NEW YORK STATE

MEDICAID PROGRAM

NURSE PRACTITIONER

PROCEDURE CODES

Table of Contents

GENERAL INFORMATION	-
SERVICES PROVIDED IN ARTICLE 28 FACILITIES	5
MMIS MODIFIERS	6
MEDICINE SECTION	8
GENERAL RULES AND INFORMATION	8
EVALUATION AND MANAGEMENT CODES	. 15
LABORATORY SERVICES PERFORMED IN THE OFFICE	. 31
DRUGS AND DRUG ADMINISTRATION	. 33
IMMUNIZATIONS	. 33
DRUGS ADMINISTERED OTHER THAN ORAL METHOD	. 37
HYDRATION, THERAPEUTIC, PROPHYLACTIC, DIAGNOSTIC INJECTIONS	45
CHEMOTHERAPY DRUGS	49
PSYCHIATRY	54
SPECIAL OPHTHALMOLOGICAL SERVICES	55
CARDIOVASCULAR	56
PULMONARY	53
ALLERGY AND CLINICAL IMMUNOLOGY	53
MISCELLANEOUS SERVICES	53
SURGERY SECTION	. 54
GENERAL INFORMATION AND RULES	55
INTEGUMENTARY SYSTEM	. 56
DIGESTIVE SYSTEM	57
FEMALE GENITAL SYSTEM	. 58
MATERNITY CARE	. 58
NERVOUS SYSTEM	59
AUDITORY SYSTEM	59

GENERAL INFORMATION

- 1. **MULTIPLE CALLS**: If an individual patient is seen on more than one occasion during a single day, the fee for each visit may be allowed.
- 2. CHARGES FOR DIAGNOSTIC PROCEDURES: Charges for special diagnostic procedures which are not considered to be a routine part of an examination (eg, ECG) are reimbursable in addition to the usual visit fee.
- 3. **SEPARATE PROCEDURE**: Certain of the listed procedures are commonly carried out as an integral part of a total service and as such do not warrant a separate charge. When such a procedure is carried out as a <u>separate entity</u>, not immediately related to other services, the indicated value for "Separate Procedure" is applicable.
- 4. REFERRAL: A referral is the transfer of the total or specific care of a patient from one physician or nurse practitioner to another and does not constitute a consultation. Initial evaluation and subsequent services are designated as listed in LEVELS OF E/M SERVICE. Referral is to be distinguished from consultation. REFERRAL is the transfer of the patient from one practitioner to another for definitive treatment.
- 5. **CONSULTATION**: is advice and opinion from an accredited physician specialist called in by the attending practitioner in regard to the further management of the patient by the attending practitioner.

Consultation fees are applicable only when examinations are provided by an accredited physician specialist within the scope of his specialty upon request of the authorizing agency or of the attending practitioner who is treating the medical problem for which consultation is required. The attending practitioner must certify that he requested such consultation and that it was incident and necessary to his further care of the patient.

When the consultant physician assumes responsibility for a portion of patient management, he will be rendering concurrent care (use appropriate level of evaluation and management codes). If he has had the case transferred or referred to him, he should then use the appropriate codes for services rendered (eg, visits, procedures) on and subsequent to the date of transfer.

6. BY REPORT: A service that is rarely provided, unusual, variable, or new may require a special report in determining medical appropriateness of the service. Pertinent information should include an adequate definition or description of the nature, extent, and need for the procedure, and the time, effort and equipment necessary to provide the service. Additional items which may be included are: Complexity of symptoms, final diagnosis, pertinent physical findings (such as size, locations, and number of lesions(s), if appropriate), diagnostic and therapeutic procedures (including major and supplementary surgical procedures, if appropriate), concurrent problems, and follow-up care.

When the value of a procedure is to be determined "By Report" (BR), information concerning the nature, extent and need for the procedure or service must be furnished in addition to the time, skill and equipment necessitated. Appropriate documentation (eg, procedure description, itemized invoices, etc.) should accompany all claims submitted.

Itemized invoices must document acquisition cost, the line item cost from a manufacturer or wholesaler net of any rebates, discounts or other valuable considerations.

7. **MATERIALS SUPPLIED BY PRACTITIONER**: Supplies and materials provided, eg, sterile trays/drugs, **over and above** those usually included with the procedure(s), office visit or other services rendered may be listed separately. List drugs, trays, supplies and materials provided. Identify as 99070 or specific supply code.

Reimbursement for supplies and material (including drugs, vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner. For all items furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the item provided.

- 8. **PRESCRIBER WORKSHEET**: Enteral formula requires voice interactive telephone prior authorization from the Medicaid program. The prescriber must initiate the authorization through this system. The worksheet specifies the questions asked on the voice interactive telephone system and must be maintained in the patient's clinical record. The worksheet can be found on the Provider Communication link. <u>eMedNY : Provider Manuals . Nurse Practitioner Provider Communications</u>
- PRIOR APPROVAL: Payment for those listed procedures where the MMIS code number is <u>underlined</u> is dependent upon obtaining the approval of the Department of Health prior to performance of the procedure. If such prior approval is not obtained, no reimbursement will be made.
- 10. RADIOLOGY PRIOR APPROVAL: Information for Ordering Providers- If you are ordering a CT, CTA, MRI, MRA, Cardiac Nuclear, or PET procedure, you or your office staff are required to obtain an approval number through the RadConsult program. Requests will be reviewed against guidelines, and a prior approval number will be issued.

Using a secure login, you will have the ability to access RadConsult Online or call the RadConsult contact center to check the status of procedure requests.

Beneficiaries who are eligible for both Medicaid and Medicare (dual eligible) or beneficiaries who are enrolled in a managed care plan are not included.

Additional information is available at <u>http://www.emedny.org/ProviderManuals/Radiology/index.html</u> Version 2022-2

- 11. **DVS AUTHORIZATION (#)**: Codes followed by **#** require an authorization via the dispensing validation system (DVS) before services are rendered.
- 12. **PAYMENT IN FULL**: Fees paid in accordance with the allowances in the Medical Fee Schedule shall be considered full payment for services rendered. No additional charge shall be made by a practitioner.
- 13. **FEES**: The fees are listed in the Nurse Practitioner Fee Schedule, available at <u>http://www.emedny.org/ProviderManuals/NursePractitioner/index.html</u>

Listed fees are the maximum reimbursable Medicaid fees. Fees for the MOMS Program and PPAC Program can be found in the Enhanced Program Fee Schedule.

SERVICES PROVIDED IN ARTICLE 28 FACILITIES

The professional component for all services provided by a nurse practitioner in an Article 28 hospital outpatient clinic, hospital inpatient setting, emergency department, ambulatory surgery setting and diagnostic and treatment center (D&TC) for Medicaid fee-for-service patients is included in the APG or APR-DRG payment to the facility. Nurse practitioners may not bill Medicaid separately for professional services provided in an Article 28 facility.

MMIS MODIFIERS

Note: NCCI associated modifiers are recognized for NCCI code pairs/related edits. For additional information please refer to the CMS website: http://www.cms.hhs.gov/NationalCorrectCodInitEd/

Under certain circumstances, the MMIS code identifying a specific procedure or service must be expanded by two additional characters to further define or explain the nature of the procedure.

The circumstances under which such further description is required are detailed below along with the appropriate modifiers to be added to the basic code when the particular circumstance applies.

- -24 <u>Unrelated Evaluation and Management Service by the Same Practitioner during a</u> <u>Postoperative Period</u>: The practitioner may need to indicate that an evaluation and management service was performed during a postoperative period for a reason(s) unrelated to the original procedure. This circumstance may be reported by adding the modifier -24 to the appropriate level of E/M service. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- -25 <u>Significant, Separately Identifiable Evaluation and Management Service by the Same</u> <u>Practitioner on the Day of a Procedure</u>: (Effective 10/1/92) The practitioner may need to indicate that on the day a procedure or service identified by an MMIS code was performed, the

Version 2022-2

patient's condition required a significant, separately identifiable E/M service above and beyond the usual preoperative and postoperative care associated with the procedure that was performed. The E/M service may be prompted by the symptom or condition, for which the procedure and/or service was provided. As such, different diagnoses are not required for reporting of the E/M services on the same date. This circumstance may be reported by adding the modifier -25 to the appropriate level of E/M service.

NOTE: This modifier is not used to report an E/M service that resulted in a decision to perform surgery. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)

- -77 <u>Repeat Procedure by Another Practitioner</u>: The practitioner may need to indicate that a basic procedure performed by another practitioner had to be repeated. This situation may be reported by adding modifier -77 to the repeated service. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- -79 <u>Unrelated Procedure or Service by the Same Practitioner During the Postoperative Period</u>: The practitioner may need to indicate that the performance of a procedure or service during the postoperative period was unrelated to the original procedure. This circumstance may be reported by using the modifier -79 to the related procedure. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- -EP <u>Child/Teen Health Program (EPSDT Program)</u>: Service provided as part of the Medicaid Early Periodic Screening, Diagnosis and Treatment (EPSDT) Program or Child/Teen Health Program will be identified by adding the modifier -EP to the usual procedure number. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- -FP <u>Service Provided as Part of Family Planning Program</u>: All Family Planning Services will be identified by adding the modifier '-FP' to the usual procedure code: number. (Reimbursement will not exceed 100% of the maximum State' Medical Fee Schedule amount.)
- -SL <u>State Supplied Vaccine</u>: (Used to identify administration of vaccine supplied by the Vaccines for Children Program (VFC) for children under 19 years of age). When administering vaccine supplied by the state (VFC program), you **must** append modifier –SL State Supplied Vaccine to the procedure code number representing the vaccine administered. Omission of this modifier on claims for recipients under 19 years of age will cause your claim to deny. (Reimbursement will not exceed \$17.85, the administration fee for the VFC program.)

MEDICINE SECTION

GENERAL RULES AND INFORMATION

- 1. **PRIMARY CARE**: Primary care is first contact care, the type furnished to individuals when they enter the health care system. Primary care is comprehensive in that it deals with a wide range of health problems, diagnosis and modes of treatment. Primary care is continuous in that an ongoing relationship is established with the primary care practitioner who monitors and provides the necessary follow-up care and is coordinated by linking patients with more varied specialized services when needed. Consultations and care provided on referral from another practitioner is not considered primary care.
- 2. CLASSIFICATION OF EVALUATION AND MANAGEMENT (E/M) SERVICES: The Federal Health Care Finance Administration has mandated that all state Medicaid programs utilize the new Evaluation and Management coding as published in the American Medical Association's <u>CPT</u>.

For the first time, a major section has been devoted entirely to E/M services. The new codes are more than a clarification of the old definitions; they represent a new way of classifying the work of practitioners. In particular, they involve far more clinical detail than the old visit codes. For this reason, it is important to treat the new codes as a new system and not make a one-for-one substitution of a new code number for a code number previously used to report a level of service defined as "brief", "limited", "intermediate", etc.

The E/M section is divided into broad categories such as office visits, hospital visits and consultations. Most of the categories are further divided into two or more subcategories of E/M services. For example, there are two subcategories of office visits (new patient and established patient) and there are two subcategories of hospital visits (initial and subsequent). The subcategories of E/M services are further classified into levels of E/M services that are identified by specific codes. This classification is important because the nature of practitioner work varies by type of service, place of service, and the patient's status.

The basic format of the levels of E/M services is the same for most categories. First, a unique code number is listed. Second, the place and/or type of service is specified, eg, office consultation. Third, the content of the service is defined, eg, comprehensive history and comprehensive examination. (See levels of E/M services following for details on the content of E/M services.) Fourth, the nature of the presenting problem(s) usually associated with a given level is described. Fifth, the time typically required to provide the service is specified.

3. **DEFINITIONS OF COMMONLY USED E/M TERMS**: Certain key words and phrases are used throughout the E/M section. The following definitions are intended to reduce the potential for differing interpretations and to increase the consistency of reporting.

<u>NEW AND ESTABLISHED PATIENT</u>: A new patient is one who has not received any professional services from the practitioner or practitioners working in the same specialty within the same group within the past three years.

An established patient is one who has received professional services from the practitioner within the past three years.

In the instance where a practitioner is on call for or covering for another practitioner, the patient's encounter will be classified as it would have been by the practitioner who is not available.

No distinction is made between new and established patients in the emergency department. E/M services in the emergency department category may be reported for any new or established patient who presents for treatment in the emergency department.

<u>CHIEF COMPLAINT</u>: A concise statement describing the symptom, problem, condition, diagnosis or other factor that is the reason for the encounter, usually stated in the patient's words.

<u>CONCURRENT CARE</u>: is the provision of similar services, eg, hospital visits, to the same patient by more than one practitioner on the same day. When concurrent care is provided, no special reporting is required. Modifier -75 has been deleted.

<u>COUNSELING</u>: Counseling is a discussion with a patient and/or family concerning one or more of the following areas:

- diagnostic results, impressions, and/or recommended diagnostic studies;
- prognosis;
- risks and benefits of management (treatment) options;
- instructions for management (treatment) and/or follow-up;
- importance of compliance with chosen management (treatment)options;
- risk factor reduction; and
- patient and family education.

<u>FAMILY HISTORY</u>: A review of medical events in the patient's family that includes significant information about:

- the health status or cause of death of parents, siblings, and children;
- specific diseases related to problems identified in the Chief Complaint or History of the Present Illness, and/or System Review;
- diseases of family members which may be hereditary or place the patient at risk.

<u>HISTORY OF PRESENT ILLNESS</u>: A chronological description of the development of the patient's present illness from the first sign and/or symptom to the present. This includes a description of location, quality, severity, timing, context, modifying factors and associated signs and symptoms significantly related to the presenting problem(s).

<u>NATURE OF PRESENTING PROBLEM</u>: A presenting problem is a disease, condition, illness, injury, symptom, sign, finding, complaint, or other reason for encounter, with or without a diagnosis being established at the time of the encounter. The E/M codes recognize five types of presenting problems that are defined as follows:

- Minimal A problem that may not require the presence of the practitioner, but service is
 provided under the practitioner's supervision.
- Self-limited or Minor A problem that runs a definite and prescribed course, is transient in nature and is not likely to permanently alter health status OR has a good prognosis with management/compliance.

- Low severity A problem where the risk of morbidity without treatment is low; there is little to no risk of mortality without treatment; full recovery without functional impairment is expected.
- Moderate severity A problem where the risk of morbidity without treatment is moderate; there is moderate risk of mortality without treatment; uncertain prognosis OR increased probability of prolonged functional impairment.
- High severity A problem where the risk of morbidity without treatment is high to extreme; there is a moderate to high risk of mortality without treatment OR high probability of severe, prolonged functional impairment.

PAST HISTORY: A review of the patient's past experiences with illnesses, injuries, and treatments that includes significant information about:

- prior major illnesses and injuries;
- prior operations;
- prior hospitalizations;
- current medications;
- allergies (e.g., drug, food);
- age appropriate immunization status;
- age appropriate feeding/dietary status.

<u>SOCIAL HISTORY</u>: an age appropriate review of past and current activities that include significant information about:

- marital status and/or living arrangements;
- current employment;
- occupational history;
- use of drugs, alcohol, and tobacco;
- level of education;
- sexual history;
- other relevant social factors.

<u>SYSTEM REVIEW (REVIEW OF SYSTEMS)</u>: An inventory of body systems obtained through a series of questions seeking to identify signs and/or symptoms which the patient may be experiencing or has experienced. The following elements of a system review have been identified:

- Constitutional symptoms (fever, weight loss, etc.)
- Eyes
- Ears, Nose, Mouth, Throat
- Cardiovascular
- Respiratory
- Gastrointestinal
- Genitourinary
- Musculoskeletal
- Integumentary (skin and/or breast)
- Neurological
- Psychiatric
- Endocrine

- Hematologic/Lymphatic
- Allergic/Immunologic

The review of systems helps define the problem, clarify the differential diagnoses, identify needed testing, or serves as baseline data on other systems that might be affected by any possible management options.

TIME: The inclusion of time in the definitions of levels of E/M services has been implicit in prior editions. The inclusion of time as an explicit factor beginning in 1992 is done to assist practitioners in selecting the most appropriate level of E/M services. It should be recognized that the specific times expressed in the visit code descriptors are averages, and therefore represent a range of times which may be higher or lower depending on actual clinical circumstances.

Time is **not** a descriptive component for the emergency department levels of E/M services because emergency department services are typically provided on a variable intensity basis, often involving multiple encounters with several patients over an extended period of time. Therefore, it is often difficult for practitioners to provide accurate estimates of the time spent face-to-face with the patient.

Intra-service times are defined as **face-to-face** time for office and other outpatient visits and as unit/floor time for hospital or other inpatient visits. This distinction is necessary because most of the work of typical office visits takes place during the face-to-face time with the patient, while most of the work of typical hospital visits takes place during the time spent on the patient's floor or unit.

A. Face-to-face time (e.g., office and other outpatient visits, office consultations and all psychiatry procedures): For coding purposes, face-to-face time for these services is defined as only that time the practitioner spends face-to-face with the patient and/or family. This includes the time in which the practitioner performs such tasks as obtaining a history, performing an examination, and counseling the patient.

Practitioners also spend time doing work before or after face-to-face time with the patient, performing such tasks reviewing records and tests, arranging for further services, and communicating further with other professionals and the patient through written reports and telephone contact.

This non face-to-face time for office services – also called pre- and post-encounter time – is not included in the time component described in the E/M codes. However, the pre- and post-face-to-face work associated with an encounter was included in calculating the total work of typical services.

Thus, the face-to-face time associated with the services described by any E/M code is a valid proxy for the total work done before, during, and after the visit.

B. **Unit/floor time (inpatient hospital care)**: For reporting purposes, intra-service time for these services is defined as unit/floor time, which includes the time that the practitioner is

present on the patient's hospital unit and at the bedside rendering services for that patient. This includes the time in which the practitioner establishes and/or reviews the patient's chart, examines the patient, writes notes and communicates with other professionals and the patient's family.

In the hospital, pre- and post-time includes time spent off the patient's floor performing such tasks as reviewing pathology and radiology findings in another part of the hospital. This pre- and post-visit time is not included in the time component described in these codes. However, the pre- and post-work performed during the time spent off the floor or unit was included in calculating the total work of typical services.

Thus, the unit/floor time associated with the services described by any code is a valid proxy for the total work done before, during and after the visit.

4A. LEVELS OF E/M SERVICES: Within each category or subcategory of E/M service, there are three to five levels of E/M services available for reporting purposes. Levels of E/M services are not interchangeable among the different categories or subcategories of service. For example, the first level of E/M services in the subcategory of office visit, new patient, does not have the same definition as the first level of E/M services in the subcategory of office visit, established patient.

The levels of E/M services include examinations, evaluations, treatments, conferences with or concerning patients, preventive health supervision, and similar medical services such as the determination of the need and/or location for appropriate care. Medical screening includes the history, examination, and medical decision-making required to determine the need and/or location for appropriate care and treatment of the patient (e.g., office and other outpatient setting, emergency department, nursing facility, etc.). The levels of E/M services encompass the wide variations in skill, effort, time, responsibility and medical knowledge required for the prevention or diagnosis and treatment of illness or injury and the promotion of optimal health.

The descriptors for the levels of E/M services recognize seven components, six of which are used in defining the levels of E/M services. These components are: history; examination, medical decision making, counseling; coordination of care; nature of presenting problem, and time.

The first three of these components (history, examination and medical decision making) are considered the key components in selecting a level of E/M services.

The next three components (counseling, coordination of care, and the nature of the presenting problem) are considered contributory factors in the majority of encounters. Although the first two of these contributory factors are important E/M services, it is not required that these services be provided at every patient encounter. The final component, time, has already been discussed in detail.

The actual performance of diagnostic tests/studies for which specific codes are available is not included in the levels of E/M services. Practitioner performance of diagnostic tests/studies for

which specific codes are available should be reported separately, in addition to the appropriate E/M code.

4B. INSTRUCTIONS FOR SELECTING A LEVEL OF E/M SERVICE:

- i. <u>IDENTIFY THE CATEGORY AND SUBCATEGORY OF SERVICE</u>: Select from the categories and subcategories of codes available for reporting E/M services.
- ii. <u>REVIEW THE REPORTING INSTRUCTIONS FOR THE SELECTED CATEGORY OR</u> <u>SUBCATEGORY</u>: Most of the categories and many of the subcategories of service have special guidelines or instructions unique to that category or subcategory. Where these are indicated, e.g., "Hospital Care", special instructions will be presented preceding the levels of E/M services.
- iii. <u>REVIEW THE LEVEL OF E/M SERVICE DESCRIPTORS AND EXAMPLES IN THE</u> <u>SELECTED CATEGORY OR SUBCATEGORY</u>: The descriptors for the levels of E/M services recognize seven components, six of which are used in defining the levels of E/M services. These components are: history, examination, medical decision making, counseling, coordination of care, nature of presenting problem, and time.

The first three of these components (i.e., history, examination and medical decision making) should be considered the key components in selecting the level of E/M services. An exception to this rule is in the case of visits which consist predominantly of counseling or coordination of care (see <u>vii.c.</u>).

The nature of the presenting problem and time are provided in some levels to assist the practitioner in determining the appropriate level of E/M service.

- iv. <u>DETERMINE THE EXTENT OF HISTORY OBTAINED</u>: The levels of E/M services recognize four types of history that are defined as follows:
 - Problem Focused chief complaint, brief history of present illness or problem.
 - Expanded Problem Focused chief complaint; brief history of present illness; problem pertinent system review.
 - Detailed chief complaint; extended history of present illness; problem pertinent system review extended to include review of a limited number of additional systems; <u>pertinent</u> past, family and/or social history directly related to the patient's problems.
 - Comprehensive chief complaint; extended history of present illness; review of systems which is directly related to the problem(s) identified in the history of the present illness plus a review of all additional body systems; <u>complete</u> past, family and social history.

The comprehensive history obtained as part of the preventive medicine evaluation and management service is not problem-oriented and does not involve a chief complaint of present illness. It does, however, include a comprehensive system review and comprehensive or interval past, family and social history as well as a comprehensive assessment/history of pertinent risk factors.

- v. <u>DETERMINE THE EXTENT OF EXAMINATION PERFORMED</u>: The levels of E/M services recognize four types of examination that are defined as follows:
 - Problem Focused a limited examination of the affected body area or organ system.
 - Expanded Problem Focused a limited examination of the affected body area or organ system and other symptomatic or related organ system(s).
 - Detailed an extended examination of the affected body area(s) and other symptomatic or related organ system(s).

Comprehensive – a general multi-system examination or a complete examination of a single organ system. NOTE: The comprehensive examination performed as part of the preventive medicine evaluation and management service is multi-system, but its extent is based on age and risk factors identified.

For the purposes of these definitions, the following organ systems are recognized: eyes, ears, nose, mouth and throat; cardiovascular; respiratory; gastrointestinal; genitourinary; musculoskeletal; skin, neurologic; psychiatric; hematologic/lymphatic/immunologic.

- vi. <u>DETERMINE THE COMPLEXITY OF MEDICAL DECISION MAKING</u>: Medical decision making refers to the complexity of establishing a diagnosis and/or selecting a management option as measured by:
 - the number of possible diagnoses and/or the number of management options that must be considered;
 - the amount and/or complexity of medical records, diagnostic tests, and/or other information that must be obtained, reviewed and analyzed; and
 - the risk of significant complications, morbidity and/or mortality, as well as co-morbidities, associated with the patient's presenting problem(s), the diagnostic procedure(s) and/or the possible management options.

Four types of medical decision making are recognized: straightforward; low complexity; moderate complexity, and, high complexity. To qualify for a given type of decision making, two of the three elements in the table following must be met or exceeded:

		J	
Number of diagnoses or	Amount and/or	Risk of complications	Type of decision
management options	complexity of data	and/or morbidity or	making
	to be reviewed	mortality	
minimal	minimal or none	minimal	straightforward
limited	limited	low	low complexity
multiple	moderate	moderate	moderate complexity
extensive	extensive	high	high complexity

Co-morbidities/underlying disease, in and of themselves, are not considered in selecting a level of E/M services unless their presence significantly increases the complexity of the medical decision making.

vii. SELECT THE APPROPRIATE LEVEL OF E/M SERVICES BASED ON THE FOLLOWING:

- a. For the following categories/subcategories, ALL OF THE KEY COMPONENTS (ie, history, examination, and medical decision making), must meet or exceed the stated requirements to qualify for a particular level of E/M service: office, new patient; hospital observation services; initial hospital care; office consultations; initial): inpatient consultations, emergency department services; initial nursing facility care; domiciliary care, new patient; and home, new patient.
- b. For the following categories/subcategories, TWO OF THE THREE KEY COMPONENTS (i.e., history, examination, and medical decision making) must meet or exceed the stated requirements to qualify for a particular level of E/M services: office, established patient; subsequent hospital care; subsequent nursing facility care; domiciliary care, established patient; and home, established patient.

c. In the case where counseling and or coordination of care dominates (more than 50%) the practitioner/patient and/or family encounter (face-to-face time in the office or other outpatient setting or floor/unit time in the hospital), then **time** is considered the key or controlling factor to qualify for a particular level of E/M services. The extent of counseling and/or coordination of care must be documented in the medical record.

<u>NOTE: CLINICAL EXAMPLES</u>: Clinical examples of the codes for E/M services are provided to assist practitioners in understanding the meaning of the descriptors and selecting the correct code.

The same problem, when seen by physicians in different specialties, may involve different amounts of work. Therefore, the appropriate level of encounter should be reported using the descriptor rather than the examples.

5. **FAMILY PLANNING CARE**: In accordance with approval received by the State Director of the Budget, effective July 1, 1973 in the Medicaid Program, all family planning services are to be reported on claims using appropriate MMIS code numbers listed in this fee schedule in combination with modifier -FP.

This reporting procedure will assure to New York State the higher level of federal reimbursement which is available when family planning services are provided to Medicaid patients (90% instead of 50% for other medical care). It will also provide the means to document conformity with mandated federal requirements on provision of family planning services.

6. EVALUATION AND MANAGEMENT SERVICES (OUTPATIENT OR INPATIENT): Evaluation and management fees do not apply to preoperative consultations or follow-up visits as designated in accordance with the surgical fees listed in the SURGERY section of the State Medical Fee Schedule.

For additional information on the appropriate circumstances governing the billing of the hospital visit procedure codes see **PRACTITIONER SERVICES PROVIDED IN HOSPITALS**.

EVALUATION AND MANAGEMENT CODES

Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs.

OFFICE OR OTHER OUTPATIENT SERVICES

The following codes are used to report evaluation and management services provided in the practitioner's office or in an outpatient or other ambulatory facility. A patient is considered an outpatient until inpatient admission to a health care facility occurs. When claiming for Evaluation and Management procedure codes report the place of service code that represents the location where the service was rendered in the claim form field for Place of Service. The maximum reimbursable amount for these codes is dependent on the Place of Service reported.

For Evaluation and Management services rendered in the practitioner's private office, report place of service "11". For services rendered in a Hospital Outpatient setting report place of service "22".

To report services provided to a patient who is admitted to a hospital or nursing facility in the course of an encounter in the office or other ambulatory facility, see the notes for initial hospital inpatient care or comprehensive nursing facility assessments.

NEW PATIENT

- 99202 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and /or examination and straightforward medical decision making. When using time for code selection, 15-29 minutes of total time is spent on the date of the encounter.
- 99203 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and /or examination and low level of medical decision making. When using time for code selection, 30-44 minutes of total time is spent on the date of the encounter.
- 99204 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and /or examination and moderate level of medical decision making. When using time for code selection, 45-59 minutes of total time is spent on the date of the encounter.
- 99205 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and /or examination and high level of medical decision making. When using time for code selection, 60-74 minutes of total time is spent on the date of the encounter.

ESTABLISHED PATIENT

The following codes are used to report the evaluation and management services provided to established patients who present for follow-up and/or periodic reevaluation of problems or for the evaluation and management of new problem(s) in established patients.

- 99211 Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional.
- 99212 Office or other outpatient visit for the evaluation and management of an established patient, which requires medically appropriate history and/ or examination and straightforward medical decision making. When using time for code selection, 10-19 minutes of total time is spent on the date of the encounter.
- 99213 Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/ or examination and low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter.
- 99214 Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/ or examination and moderate level of Version 2022-2

medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter.

99215 Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/ or examination and high level of medical decision making. When using time for code selection 40-54 minutes of total time is spent on the date of the encounter

HOSPITAL OBSERVATION SERVICES

The following codes are used to report evaluation and management services provided to patients designated/admitted as "observation status" in a hospital. It is not necessary that the patient be located in an observation are designated by the hospital. If such an area does exist in a hospital (as a separate unit in the hospital, in the emergency department, etc.), these codes are to be utilized if the patient is placed in such an area.

Typical times have not yet been established for this category of services.

OBSERVATION CARE DISCHARGE SERVICES

Observation care discharge of a patient from "observation status" includes final examination of the patient, discussion of the hospital stay, instructions for continuing care, and preparation of discharge records. For observation or inpatient hospital care including the admission and discharge of the patient on the same date, see codes 99234-99236 as appropriate.

99217 Observation care discharge day management (This code is to be utilized by the practitioner to report all services provided to a patient on discharge from outpatient hospital "observation status" if the discharge is on other that the initial date of "observation status". To report services to a patient designated as "observation status" or "inpatient status" and discharged on the same date, use the codes for Observation or Inpatient Care Services (99234-99236).

INITIAL OBSERVATION CARE - NEW OR ESTABLISHED PATIENT

The following codes are used to report the encounter(s) by the supervising practitioner with the patient when designated as "observation status". This refers to the initiation of observation status, supervision of the care plan for observation and performance of periodic reassessments.

To report services provided to a patient who is admitted to the hospital after receiving hospital observation care services on the same date, see the notes for initial hospital inpatient care. For a patient admitted to the hospital on a date subsequent to the date of observation status, the hospital admission would be reported with the appropriate initial hospital care codes (99221-99223). For a patient admitted and discharged from observation or inpatient status on the same date, the services should be reported with codes 99234-99236 as appropriate. Do not report observation discharge (99217) in conjunction with the hospital admission.

When "observation status" is initiated in the course of an encounter in another site of service (e.g., hospital emergency department, practitioner's office, nursing facility) all evaluation and management services provided by the supervising practitioner in conjunction with initiating "observation status" are

Version 2022-2

considered part of the initial observation care when performed on the same date. The observation care level of service reported by the supervising practitioner should include the services related to initiating "observation status" provided in the other sites of service as well as in the observation setting. Evaluation and Management services on the same date provided in sites that are related to initiating "observation status" should NOT be reported separately.

These codes may not be utilized for post-operative recovery if the procedure is considered a part of the surgical "package". These codes apply to all Evaluation and Management services that are provided on the same date of initiating "observation status".

99218 Initial observation care, per day, for the evaluation and management of a patient which requires these 3 key components:

- a detailed or comprehensive history;
- a detailed or comprehensive examination; and
- medical decision making that is straightforward or of low complexity.

Usually the problem(s) requiring admission to outpatient hospital "observation status" are of low severity. Physicians typically spend 30 minutes at the bedside and on the patient's hospital floor or unit.

99219 Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of moderate complexity.

Usually the problem(s) requiring admission to outpatient hospital "observation status" are of moderate severity. Physicians typically spend 50 minutes at the bedside and on the patient's hospital floor or unit.

99220 Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of high complexity.

Usually the problem(s) requiring admission to outpatient hospital "observation status" are of high severity. Physicians typically spend 70 minutes at the bedside and on the patient's hospital floor or unit.

SUBSEQUENT OBSERVATION CARE

All levels of subsequent observation care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient's status (ie, changes in history, physical condition, and response to management) since the last assessment by the physician. 99224 Subsequent observation care, per day, for the evaluation and management of a patient, which

requires at least 2 of these 3 key components:

- problem focused interval history;
- problem focused examination;
- medical decision making that is straightforward or of low complexity.

Usually, the patient is stable, recovering, or improving. Physicians typically spend 15 minutes at the bedside and on the patient's hospital floor or unit.

99225 Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- an expanded problem focused interval history;
- an expanded problem focused examination;
- medical decision making of moderate complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 minutes at the bedside and on the patient's hospital floor or unit.

99226 Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a detailed interval history;
- a detailed examination;

• medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant complication or a significant new problem. Physicians typically spend 35 minutes at the bedside and on the patient's hospital floor or unit.

HOSPITAL INPATIENT SERVICES

The following codes are used to report evaluation and management services provided to inpatients.

INITIAL HOSPITAL CARE - NEW OR ESTABLISHED PATIENT

The following codes are used to report the first hospital encounter with the patient by the admitting practitioner. For subsequent hospital care codes (99231-99233) as appropriate.

99221 Initial hospital care, per day, for the evaluation and management of a patient which requires these three key components:

- a detailed or comprehensive history,
- a detailed or comprehensive examination, and
- medical decision making that is straightforward or of low complexity.

Usually, the problem(s) requiring admission are of low severity. Practitioners typically spend 30 minutes at the bedside and on the patient's hospital floor or unit.

99222 Initial hospital care, per day, for the evaluation and management of a patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of moderate complexity.

Usually, the problem(s) requiring admission are of moderate severity. Practitioners typically spend 50 minutes at the bedside and on the patient's hospital floor or unit.

99223 Initial hospital care, per day, for the evaluation and management of a patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of high complexity.

Usually, the problem(s) requiring admission are of high severity. Practitioners typically spend 70 minutes at the bedside and on the patient's hospital floor or unit.

SUBSEQUENT HOSPITAL CARE

All levels of subsequent hospital care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient's status, (i.e., changes in history, physical condition and response to management) since the last assessment by the practitioner.

99231 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:

- a problem focused interval history,
- a problem focused examination, and/or
- medical decision making that is straightforward or of low complexity.

Usually, the patient is stable, recovering or improving. Practitioners typically spend 15 minutes at the bedside and on the patient's hospital floor or unit.

- 99232 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:
 - an expanded problem focused interval history,
 - an expanded problem focused examination, and/or
 - medical decision making of moderate complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Practitioners typically spend 25 minutes at the bedside and on the patient's hospital floor or unit.

- 99233 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:
 - a detailed interval history,
 - a detailed examination, and/or
 - medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant complication or a significant new problem. Practitioners typically spend 35 minutes at the bedside and on the patient's hospital floor or unit

OBSERVATION OR INPATIENT CARE SERVICES (INCLUDING ADMISSION AND DISCHARGE SERVICES)

The following codes are used to report observation or inpatient hospital care services provided to patients admitted and discharged on the same date of service. When a patient is admitted to the hospital from observation status on the same date, the practitioner should report only the initial hospital care code. The initial hospital care code reported by the admitting practitioner should include the services related to the observation status services he/she provided on the same date of inpatient admission.

When "observation status" is initiated in the course of an encounter in another site of service (e.g., hospital emergency department, practitioner's office, nursing facility) all evaluation and management services provided by the supervising practitioner in conjunction with initiating "observation status" are considered part of the initial observation care when performed on the same date. The observation **Version 2022-2**

care level of service should include the services related to initiating "observation status" provided in the other sites of service as well as in the observation setting when provided by the same practitioner.

99234 Observation or inpatient hospital care, for the evaluation and management of a patient

- including admission and discharge on the same date which requires these three key components:
 - a detailed or comprehensive history;
 - a detailed or comprehensive examination; and
 - medical decision making that is straightforward or of low complexity.

Usually the presenting problem(s) requiring admission are of low severity.

- 99235 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:
 - a comprehensive history;
 - a comprehensive examination; and
 - medical decision making of moderate complexity.

Usually the presenting problem(s) requiring admission are of moderate severity.

99236 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of high complexity.

Usually the presenting problem(s) requiring admission are of high severity.

HOSPITAL DISCHARGE SERVICES

The hospital discharge day management codes are to be used to report the total duration of time spent by a practitioner for final hospital discharge of a patient. The codes include, as appropriate, final examination of the patient, discussion of the hospital stay, even if the time spent by the practitioner on that date is not continuous, instructions for continuing care to all relevant caregivers, and preparation of discharge records, prescriptions and referral forms. For patients admitted and discharged from observation or inpatient status on the same date, the service should be reported with codes 99234-99236 as appropriate.

99238	Hospital discharge day management; 30 minutes or less
99239	more than 30 minutes

(These codes are to be utilized by the practitioner to report all services provided to a patient on the date of discharge, if other than the initial date of inpatient status. To report services to a patient who is admitted as an inpatient, and discharge on the same date, see codes 99234-99236 for observation or inpatient hospital care including the admission and discharge of the patient on the same date. To report concurrent care services provided by a practitioner(s) other than the attending practitioner, use subsequent hospital care codes (99231-99233) on the day of discharge.)

Version 2022-2

EMERGENCY DEPARTMENT SERVICES - NEW OR ESTABLISHED PATIENT

The following codes are used to report evaluation and management services provided in the emergency department. No distinction is made between new and established patients in the emergency department.

An emergency department is defined as an organized hospital based facility for the provision of unscheduled episodic services to patients who present for immediate medical attention.

The facility must be available 24 hours a day.

99281 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- a problem focused history,
- a problem focused examination, and
- straightforward medical decision making.

Usually, the presenting problem(s) are self-limited or minor.

99282 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- medical decision making of low complexity.
- Usually, the presenting problem(s) are of low to moderate severity.

99283 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate severity.

99284 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- a detailed history;
- a detailed examination; and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of high severity and require urgent evaluation by the physician but do not pose an immediate significant threat to life or physiologic function.

99285 Emergency department visit for the evaluation and management of a patient, which requires these three key components within the constraints imposed by the urgency of the patient's clinical condition and/or mental status:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of high complexity.

Usually, the presenting problem(s) are of high severity and pose an immediate significant threat to life or physiologic function.

NURSING FACILITY SERVICES

The following codes are used to report evaluation and management services to patients in Nursing Facilities (formerly called Skilled Nursing Facilities (SNFs), Intermediate Care Facilities (ICFs) or Long Term Care Facilities (LTCFs)).

INITIAL NURSING FACILITY CARE – NEW OR ESTABLISHED PATIENT

More than one comprehensive assessment may be necessary during an inpatient confinement.

99304 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a detailed or comprehensive history;
- a detailed or comprehensive examination; and
- medical decision making that is straightforward or of low complexity.

Usually, the problem(s) requiring admission are of low severity. Physicians typically spend 25 minutes at the bedside and on the patient's facility floor or unit.

99305 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of moderate complexity.

Usually, the problem(s) requiring admission are of moderate severity. Physicians typically spend 35 minutes at the bedside and on the patient's facility floor or unit.

99306 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of high complexity.

Usually, the problem(s) requiring admission are of high severity. Physicians typically spend 45 minutes at the bedside and on the patient's facility floor or unit.

SUBSEQUENT NURSING FACILITY CARE

The following codes are used to report the services provided to residents of nursing facilities who do not require a comprehensive assessment, and/or who have not had a major, permanent change of status.

All levels of subsequent nursing facility care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient's status (ie, changes in history, physical condition, and response to management) since the last assessment by the physician.

99307 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a problem focused interval history;
- a problem focused examination;
- straightforward medical decision making.

Usually, the patient is stable, recovering, or improving. Physicians typically spend 10 minutes at the bedside and on the patient's facility floor or unit.

99308 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- an expanded problem focused interval history;
- an expanded problem focused examination;
- medical decision making of low complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 15 minutes at the bedside and on the patient's facility floor or unit.

99309 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a detailed interval history;
- a detailed examination;
- medical decision making of moderate complexity.

Usually, the patient has developed a significant complication or a significant new problem. Physicians typically spend 25 minutes at the bedside and on the patient's facility floor or unit.

99310 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a comprehensive interval history;
- a comprehensive examination;
- medical decision making of high complexity.

The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Physicians typically spend 35 minutes at the bedside and on the patient's facility floor or unit.

NURSING FACILITY DISCHARGE SERVICES

The nursing facility discharge day management codes are to be used to report the total duration of time spent by a practitioner for the final nursing facility discharge of patient. The codes include, as appropriate, final examination of the patient, discussion of the nursing facility stay, even if the time spent by the practitioner on that date is not continuous. Instructions are given for continuing care to all relevant caregivers, and preparation of discharge records, prescriptions and referral forms.

99315 Nursing facility discharge day management; 30 minutes or less 99316 more than 30 minutes

DOMICILIARY, REST HOME (e.g., BOARDING HOME), OR CUSTODIAL CARE SERVICES

The following codes are used to report evaluation and management services in a facility which provides room, board and other personal assistance services, generally on a long-term basis. The facility's services do not include a medical component.

NEW PATIENT

99324 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a problem focused history,
 - a problem focused examination, and
- medical decision making that is straightforward.

Usually, the presenting problem(s) are of low severity. Practitioners typically spend 20 minutes with the patient and/or family or caregiver.

99325 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Practitioners typically spend 30 minutes with the patient and/or family or caregiver.

99326 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a detailed history,
- a detailed examination, and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high complexity. Practitioners typically spend 45 minutes with the patient and/or family or caregiver.

99327 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 60 minutes with the patient and/or family or caregiver.

99328 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant new problem requiring immediate physician attention. Practitioners typically spend 75 minutes with the patient and/or family or caregiver.

ESTABLISHED PATIENT

99334 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a problem focused interval history,
- a problem focused examination, and/or
- medical decision making that is straightforward.

Usually, the presenting problem(s) are self-limited or minor. Practitioners typically spend 15 minutes with the patient and/or family or caregiver.

99335 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- an expanded problem focused interval history,
- an expanded problem focused examination, and/or
- medical decision making of low complexity.

Usually, the presenting problem(s) are of low to moderate severity. Practitioners typically spend 25 minutes with the patient and/or family or caregiver.

99336 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a detailed interval history,
- a detailed examination, and/or
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 40 minutes with the patient and/or family or caregiver.

99337 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a comprehensive interval history,
- a comprehensive examination, and
- medical decision making of moderate to high complexity.

Usually, the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Practitioners typically spend 60 minutes with the patient and/or family or caregiver.

HOME SERVICES

The following codes are used to report evaluation and management services provided in a private residence.

NEW PATIENT

99341 Home visit for the evaluation and management of a new patient, which requires these three key components:

- a problem focused history,
- a problem focused examination, and
- medical decision making that is straightforward.

Usually the presenting problem(s) are of low severity. Practitioners typically spend 20 minute face-to-face with the patient and/or family.

99342 Home visit for the evaluation and management of a new patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Practitioners typically spend 30 minutes face-to-face with the patient and/or family.

- 99343 Home visit for the evaluation and management of a new patient, which requires these three key components:
 - a detailed history,
 - a detailed examination, and
 - medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 45 minutes face-to-face with patient and/or family.

99344 Home visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination; and
- medical decision making of moderate complexity.

Usually the presenting problem(s) are of high severity. Practitioners typically spend 60 minutes face-to-face with the patient and/or family.

99345 Home visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination; and
- medical decision making of high complexity.

Usually the patient is unstable or has developed a significant new problem requiring immediate Practitioner attention. Practitioners typically spend 75 minutes face-to-face with the patient and/or family.

ESTABLISHED PATIENT

- 99347 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
 - a problem focused interval history;
 - a problem focused examination and
 - straightforward medical decision making.

Usually the presenting problem(s) are self-limited or minor. Practitioners typically spend 15 minutes face-to-face with the patient and/or family.

99348 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- an expanded problem focused interval history;
- an expanded problem focused examination;
- medical decision making of low complexity.

Usually the presenting problem(s) are of low to moderate severity. Practitioners typically spend 25 minutes face-to-face with the patient and/or family.

99349 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a detailed interval history;
- a detailed examination;
- medical decision making of moderate complexity.

Usually the presenting problem(s) are of moderate to high severity. Practitioners typically spend 40 minutes face-to-face with the patient and/or family.

99350 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a comprehensive interval history;
- a comprehensive examination;
- medical decision making of moderate to high complexity.

Usually the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate practitioner attention. Practitioners typically spend 60 minutes face-to-face with the patient and/or family.

PROLONGED SERVICES WITH OR WITHOUT DIRECT PATIENT CONTACT ON THE DATE OF AN OFFICE VISIT OR OTHER OUTPATIENT SERVICE

99417 Prolonged office or other outpatient evaluation and management service(s) beyond the minimum required time of the primary procedure which has been selected using total time, requiring total time with or without direct patient contact beyond the usual service on the date of primary service, each 15 minutes of total time (List separately in addition to codes 99205,99215 for office or other outpatient Evaluation and Management services)

PREVENTIVE MEDICINE SERVICES

The following codes are used to report well visit services.

NEW PATIENT

- 99381 Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)
- 99382 early childhood (age 1 through 4 years)
- 99383 late childhood (age 5 through 11 years)
- adolescent (age 12 through 17 years)
- 99385 18-39 years
- 99386 40-64 years
- 99387 65 years and older

ESTABLISHED PATIENT

- 99391 Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant
 - (age younger than 1 year)
- 99392 early childhood (age 1 through 4 years)
- 99393 late childhood (age 5 through 11 years)
- adolescent (age 12 through 17 years)
- 99395 18 39 years
- 99396 40 64 years
- 99397 65 years and older

COUNSELING RISK FACTOR REDUCTION AND BEHAVIOR CHANGE INTERVENTION

BEHAVIOR CHANGE INTERVENTIONS, INDIVIDUAL

- 99406 Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes
- 99407 intensive, greater than 10 minutes

Non-Face-to-Face Services

Telephone Services

Telephone services are non-face-to-face evaluation and management (E/M) services provided to a patient using the telephone by a physician or other qualified health care professional, who may report evaluation and management services. These codes are used to report episodes of patient care initiated by an established patient or guardian of an established patient. If the telephone service ends with a decision to see the patient within 24 hours or next available urgent visit appointment, the code

is not reported; rather the encounter is considered part of the preservice work of the subsequent E/M service, procedure, and visit. Likewise, if the telephone call refers to an E/M service performed and reported by that individual within the previous seven days (either requested or unsolicited patient follow-up) or within the postoperative period of the previously completed procedure, then the service(s) is considered part of that previous E/M service or procedure. (Do not report 99441-99443, if 99421, 99422, 99423 have been reported by the same provider in the previous seven days for the same problem.)

(For telephone services provided by a qualified nonphysician who may not report evaluation and management services [eg, speech-language pathologists, physical therapists, occupational therapists, social workers, dietitians), see 98966-98968

- 99441 Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion
- 99442 11-20 minutes of medical discussion

99443 21-30 minutes of medical discussion

NEWBORN CARE SERVICES

The following codes are used to report the services provided to newborns (birth through the first 28 days) in several different settings. Use of the newborn codes is limited to the initial care of the newborn in the first days after birth prior to home discharge.

- 99460 Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant
- 99462 Subsequent hospital care, per day, for evaluation and management of normal newborn
- 99463 Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant admitted and discharged on the same date

LABORATORY SERVICES PERFORMED IN THE OFFICE

Certain laboratory procedures specified below are eligible for direct nurse practitioner reimbursement when performed in the office of the nurse practitioner in the course of treatment of her own patients.

The nurse practitioner must be registered with the federal Health Care Finance Administration (HCFA) to perform laboratory procedures as required by the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA '88).

Procedures other than those specified must be performed by a laboratory, holding a valid clinical laboratory permit in the commensurate laboratory, specialty issued by the New York State Department of Health or, where appropriate, the New York City Department of Health.

For detection of pregnancy, use code 81025.

Procedure code 85025, complete blood count (CBC), may not be billed with its component codes 85007, 85013, 85018, 85041 or 85048.

- 81000 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy
- 81001 automated, with microscopy
- 81002 non-automated, without microscopy
- 81003 automated, without microscopy
- 81015 Urinalysis; microscopic only
- 81025 Urine pregnancy test, by visual color comparison methods
- 83655 Lead
- 85007 Blood count; blood smear, microscopic examination with manual differential WBC count
- 85013 spun microhematocrit
- 85018 hem<mark>ogl</mark>obin (Hgb)
- 85025 complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count
- 85041 red blood cell (RBC) automated
- 85048 leukocyte (WBC), automated
- 85651 Sedimentation rate, erythrocyte; non-automated
- 85652 automated
- 86701 Antibody; HIV-1
- 86703 HIV-1 and HIV-2, single result
- 87081 Culture, presumptive, pathogenic organisms, screening only;
- 87651 Streptococcus, group A, amplified probe technique
- 87806 HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies
- 87880 Streptococcus, group A
- 87426 Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19])
- 87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
- 87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique
- 87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
- 87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

NOTE: Medicare reimburses for these services at 100 percent. No Medicare co-insurance payments may be billed for the above listed procedure codes.

DRUGS AND DRUG ADMINISTRATION

IMMUNIZATIONS

If a significantly separately identifiable Evaluation and Management services (eg, office service, preventative medicine services) is performed, the appropriate E/M code should be reported in addition to the vaccine and toxoid codes.

Immunizations are usually given in conjunction with a medical service. When an immunization is the only service performed, a minimal service may be listed in addition to the injection. Immunization procedures include reimbursement for the supply of materials and administration.

Reimbursement for drugs (including vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

IMMUNE GLOBULINS

Immune globulin products listed here include broad-spectrum and anti-infective immune globulins, antitoxins, and various isoantibodies.

- 90291 Cytomegalovirus immune globulin (CMV-lgIV), human, for intravenous use
- 90371 Hepatitis B immune globulin (HBlg), human, for intramuscular use
- 90375 Rabies immune globulin (Rlg), human, for intramuscular and/or subcutaneous
- 90376 Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use
- 90377 Rabies immune globin, heat-and solvent/detergent-treated (RIg-HT S/D), human, for intramuscular and /or subcutaneous use
- 90378 Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each
- 90384 Rho(D) immune globulin (Rhlg), human, full-dose, for intramuscular use
- 90385 Rho(D) immune globulin (Rhlg), human, mini-dose, for intramuscular use
- 90386 Rho(D) immune globulin (RhlgIV), human, for intravenous use
- 90389 Tetanus immune globulin (Tlg), human, for intramuscular use
- 90393 Vaccinia immune globulin, human, for intramuscular use
- 90396 Varicella-zoster immune globulin, human, for intramuscular use
- 90399 Unlisted immune globulin

IMMUNIZATION ADMINISTRATION FOR VACCINES/TOXOIDS

- 90460 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered)
- 90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
- 90472 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (list separately in addition to code for primary procedure))
- 90473 Immunization administration by intranasal or oral route; one vaccine (single or combination vaccine/toxoid)
- 90474 Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (list separately in addition to code for primary procedure)

VACCINES/TOXOIDS

For dates of service on or after 7/1/03 when immunization materials are supplied by the Vaccines for Children Program (VFC), bill using the procedure code that represents the immunization(s) administered and **append modifier –SL State Supplied Vaccine** to receive the VFC administration fee. See Modifier Section for further information.

For administration of vaccines supplied by VFC, including influenza and pneumococcal administration, providers will be required to bill vaccine administration code 90460. Providers must continue to bill the specific vaccine code with the "SL" modifier on the claim (payment for "SL" will be \$0.00). If an administration code is billed without a vaccine code with "SL", the claim will be denied. For reimbursement purposes, the administration of the components of a combination vaccine will continue to be considered as one vaccine administration. More than one vaccine administration is reimbursable under 90460 on a single date of service.

NOTE: The maximum fees for immunization injection codes are adjusted periodically by the State to reflect the current acquisition cost of the antigen. For immunizations not supplied by the VFC Program insert acquisition cost in amount charged field on claim form. For codes listed **BR/Report required**, also attach itemized invoice to claim form.

To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (eg, Vaccine Adverse Event Reporting System) the exact vaccine product administered needs to be reported with modifier -SL. Multiple codes for a particular vaccine are provided in CPT when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg, hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration.

Separate codes are available for combination vaccines (eg, DTP-Hib, DtaP-Hib, HepB-Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the Unlisted procedure code should be reported, until a new code becomes available.

- 90585 Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use
- 90586 Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use
- 90620 Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B, (MenB-4C),2 dose schedule, for intramuscular use
- 90621 Meningococcal recombinant lipoprotein vaccine, Serogroup B, (MenB-FHpb), 2 or 3 dose schedule, for intramuscular use
- 90630 Influenza vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use
- 90632 Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
- 90633 Hepatitis A vaccine (Hep A),pediatric/adolescent dosage-2 dose schedule, for intramuscular use
- 90636 Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use
- 90647 Haemophilus influenza type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use
- 90648 Haemophilus influenza type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use
- 90649 Human Papillomavirus vaccine, types 6, 11, 16, 18 quadrivalent (4vHPV), 3 dose schedule, for intramuscular use
- 90650 Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use
- 90651 Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use
- 90653 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use
- 90654 Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use
- 90655 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use
- 90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5mL dosage, for intramuscular use
- 90657 Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use
- 90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage for intramuscular use
- 90660 Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use
- 90661 Influenza virus vaccine trivalent(ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
- 90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
- 90670 Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use
- 90671 Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use
- 90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
- 90673 Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
- 90674 Influenza virus vaccine; quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use

Version 2022-2

- 90675 Rabies vaccine, for intramuscular use
- 90676 Rabies vaccine, for intradermal use
- 90677 Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use
- 90680 Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use
- 90681 Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use
- 90682 Influenza virus vaccine, quadrivalent (RIV4),derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
- 90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use
- 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
- 90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
- 90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use 90690 Typhoid vaccine, live, oral
- 90691 Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use
- 90694 Influenza virus vaccine, quadrivalent, (allV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use.
- 90696 Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine, (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use
- 90698 Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type B, and inactivated poliovirus vaccine, (DTaP –IPV/Hib), for intramuscular use
- 90700 Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
- 90702 Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use
- 90707 Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use
- 90710 Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use
- 90713 Poliovirus vaccine, inactivated, (IPV), for subcutaneous or intramuscular use
- 90714 Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use
- 90715 Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use
- 90716 Varicella virus vaccine (VAR), live, for subcutaneous use
- 90717 Yellow fever vaccine, live, for subcutaneous use
- 90723 Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine, (DTaP-HepB-IPV), for intramuscular use
- 90732 Pneumococcal polysaccharide vaccine, 23-valent, (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use
- 90733 Meningococcal polysaccharide vaccine, serogroups A,C,Y,W-135,quadrivalent (MPSV4),for subcutaneous use
- 90734 Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use
- 90736 Zoster (shingles) vaccine, (HZV), live, for subcutaneous injection
- 90738 Japanese encephalitis virus vaccine, inactivated, for intramuscular use

Version 2022-2

- 90739 Hepatitis B vaccine (HepB), adult dosage, 2 dose schedule, for intramuscular use
- 90740 Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use
- 90743 Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use
- 90744 Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use
- 90746 Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
- 90747 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use
- 90748 Hepatitis B and Haemophilus influenza type b (Hib-HepB), for intramuscular use
- 90749 Unlisted vaccine/toxoid
- 90750 Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use
- 90756 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 ml dosage, for intramuscular use
- 90759 Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use

DRUGS ADMINISTERED OTHER THAN ORAL METHOD

The following list of drugs can be injected either subcutaneous, intramuscular or intravenously. A listing of chemotherapy drugs can be found in the Chemotherapy Section.

New York State Medicaid's policy for coverage of drugs administered by subcutaneous, intramuscular or intravenous methods in the physician's office is as follows: These drugs are covered for FDA approved indications and those recognized off-label indications listed in the drug compendia (the American Hospital Formulary Service Drug Information, United States Pharmacopeia-Drug Information, the DrugDex information system or Facts and Comparisons). In the absence of such a recognized indication, an approved Institutional Review Board (IRB) protocol would be required with documentation maintained in the patient's clinical file. Drugs are not covered for investigational or experimental use.

Reimbursement for drugs (including vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice.

New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

NOTE: The maximum fees for these drugs are adjusted periodically by the State to reflect the estimated acquisition cost. Insert acquisition cost per dose in amount charged field on claim form. For codes listed as BR in the Fee Schedule, also attach an itemized invoice to claim form.

THERAPEUTIC INJECTIONS (Maximum fee includes cost of materials)

- J0121 Omadacycline, 1 mg
- J0129 Abatacept, 10 mg
 - (Administered under direct physician supervision, not for self-administration)
- J0135 Adalimumab, 20 mg
- J0153 Adenosine, 1 mg
- (Not to be used to report any adenosine phosphate compounds, instead use unlisted code)
- J0171 Adrenalin, epinephrine, 0.1 mg
- J0180 Agalsidase beta, 1 mg
- J0185 Aprepitant, 1 mg
- J0202 Alemtuzumab, 1 mg
- J0205 Alglucerase, per 10 units
- J0207 Amifostine, 500 mg
- J0210 Methyldopate HCI, up to 250 mg
- J0215 Alefacept, 0.5 mg
- J0219 Avalglucosidase alfa-ngpt, 4 mg
- J0222 Patisiran, 0.1 mg
- J0223 Givosiran, 0.5 mg
- J0224 Lumasiran, 0.5mh
- J0256 Alpha 1proteinase inhibitor (human), not otherwise specified, 10 mg
- <u>J0270</u> Alprostadil, per 1.25 mcg (Administered under direct physician supervision, not for self-administration)
- <u>J0275</u> Alprostadil urethral suppository (Administered under direct physician supervision, not for self-administration)
- J0280 Aminophylline, up to 250 mg
- J0290 Ampicillin sodium, up to 500 mg
- J0291 Plazomicin, 5 mg
- J0295 Ampicillin sodium/sulbactam sodium, per 1.5 gm
- J0300 Amobarbital, up to 125 mg
- J0360 Hydralazine HCl, up to 20 mg
- J0380 Metaraminol bitartrate, per 10 mg
- J0390 Chloroquine HCl, up to 250 mg
- J0456 Azithromycin, 500 mg
- J0461 Atropine sulfate, 0.01 mg
- J0470 Dimercaprol, per 100 mg
- J0475 Baclofen, 10 mg
- J0491 Anifrolumab-fnia, 1 mg
- J0500 Dicyclomine HCl, up to 20 mg
- J0515 Benztropine mesylate, per 1 mg
- J0517 Benralizumab, 1 mg
- J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg
- J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units
- J0561 Penicillin G benzathine, 100,000 units
- J0565 Bezlotoxumab, 10 mg
- J0584 Burosumab-twza, 1mg
- J0585 OnabotulinumtoxinaA, 1 unit

J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0593 Lanadelumab-flys\o, 1 mg (Administered under direct physician supervision, not for self-administration) J0599 C1 esterase inhibitor (human), (haegarda), 10 units **J0600** Edetate calcium disodium, up to 1000 mg **J0610** Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin, not otherwise specified, 0.5 mg Levoleucovorin (khapzory), 0.5 mg J0642 J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg Sterile cefuroxime sodium, per 750 mg J0697 Cefotaxime sodium, per gm J0698 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg Ceftizoxime sodium, per 500 mg J0715 Chloramphenicol sodium succinate, up to 1 gm J0720 Chorionic gonadotropin, per 1,000 USP units J0725 J0740 Cidofovir, 375 mg Cabotegravir and rilpivirine, 2mg/3mg J0741 Ciprofloxacin for intravenous infusion, 200 mg J0744 J0745 Codeine phosphate, per 30 mg Colistimethate sodium, up to 150 mg J0770 J0780 Prochlorperazine, up to 10 mg Crizanlizumab-tmca, 5mg J0791 J0834 Cosyntropin 0.25 mg J0875 Dalbavancin, 5 mg Darbepoetin alfa, 1 mcg (Non-ESRD use) J0881 Epoetin alfa, (Non-ESRD use), 1000 units J0885 Epoetin beta, 1 mcg (Non-ESRD-use) J0888 J0894 Decitabine, 1 mg J0895 Deferoxamine mesylate, 500 mg Luspatercept-aamt, 0.25 mg J0896 Brompheniramine maleate, per 10 mg J0945 J1000 Depo-estradiol cypionate, up to 5 mg J1020 Methylprednisolone acetate, 20 mg J1030 Methylprednisolone acetate, 40 mg Methylprednisolone acetate, 80 mg J1040 J1050 Injection, medroxyprogesterone acetate, 1 mg Version 2022-2

J1071 Testosterone cypionate, 1 mg J1094 Dexamethasone acetate, 1 mg J1100 Dexamethasone sodium phosphate, 1 mg J1110 Dihydroergotamine mesylate, per 1 mg J1120 Acetazolamide sodium, up to 500 mg J1160 Digoxin, up to 0.5 mg J1165 Phenytoin sodium, per 50 mg J1170 Hydromorphone, up to 4 mg J1180 Dyphylline, up to 500 mg J1190 Dexrazoxane HCl, per 250 mg Diphenhydramine HCl, up to 50 mg J1200 J1205 Chlorothiazide sodium, per 500 mg J1212 DMSO, dimethyl sulfoxide, 50%, 50 ml Methadone HCI, up to 10 mg J1230 Dimenhydrinate, up to 50 mg J1240 Dolasetron mesylate, 10 mg J1260 Eculizumab, 10 mg J1300 Edaravone, 1 mg J1301 J0305 Evinacumab-dgnb, 5mg J1320 Amitriptyline HCl, up to 20 mg J1322 Elosulfase alfa, 1 mg Ergonovine maleate, up to 0.2 mg J1330 J1364 Erythromycin lactobionate, per 500 mg J1380 Estradiol valerate, up to 10 mg J1410 Estrogen conjugated, per 25 mg Viltolarsen, 10 mg J1427 J1435 Estrone, per 1 mg Etidronate disodium, per 300 mg J1436 J1437 Ferric derisomaltose, 10 mg J1438 Etanercept, 25 mg (Administered under direct physician supervision, not self-administered) Ferric Carboxymaltose, 1 mg J1439 Filgrastim (G CSF), excludes biosimilars, 1 microgram J1442 J1447 Tbo-Filgrastim, 1 microgram Trilaciclib, 1mg J1448 J1450 Fluconazole, 200 mg J1452 Fomivirsen sodium, intraocular, 1.65 mg J1453 Fosaprepitant, 1 mg J1454 Fosnetupitant 235 mg and palonestron 0.25 mg J1455 Foscarnet sodium, per 1000 mg J1458 Galsulfase, 1 mg Immune globulin (Privigen), intravenous, non lyophilized (e.g. liquid), 500 mg J1459 Gamma globulin, intramuscular, 1 cc J1460 J1554 Immune globulin (Asceniv), 500 mg Immune Globulin (Cuvitru), 100 mg J1555 Version 2022-2

- J1556 Immune Globulin (Bivigam), 500 mg
- J1560 Gamma globulin, intramuscular, over 10 cc
- J1561 Immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g. liquid), 500 mg
- J1562 Immune globulin (Vivaglobin), 100 mg
- J1566 Immune globulin, intravenous, lyophilized (e.g. powder), not otherwise specified, 500 mg
- J1568 Immune globulin, (Octagam), intravenous, non-lyophilized (e.g. liquid), 500 mg
- J1569 Immune globulin, (Gammagard Liquid), non-lyophilized, (e.g. liquid), 500 mg
- J1570 Ganciclovir sodium, 500 mg
- J1572 Immune globulin, (flebogamma/flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg
- J1573 Hepatitis B immune globulin (HepaGam B), intravenous, 0.5 ml
- J1575 Jmmune Globulin/Hyaluronidase (HYQVIA), 100 mg
- J1580 Garamycin, gentamicin, up to 80 mg
- J1595 Glatiramer acetate, 20 mg
- J1599 Immune globulin, intravenous, non-lyophilized (e.g. liquid), not otherwise specified, 500 mg
- J1600 Gold sodium thiomalate, up to 50 mg
- J1602 Golimumab, per 1 mg for Intravenous use
- J1610 Glucagon HCl, per 1 mg
- J1620 Gonadorelin HCl, per 100 mcg
- J1626 Granisetron HCI, 100 mcg
- J1627 Granisetron, extended-release, 0.1 mg
- J1628 Guselkumab, 1 mg
- J1630 Haloperidol, up to 5 mg
- J1631 Haloperidol decanoate, per 50 mg
- J1642 Heparin sodium, (heparin lock flush), per 10 units
- J1644 Heparin sodium, per 1000 units
- J1645 Dalteparin sodium, per 2500 IU
- J1652 Fondaparinux sodium, 0.5 mg
- J1655 Tinzaparin sodium, 1000 IU
- J1710 Hydrocortisone sodium phosphate, up to 50 mg
- J1720 Hydrocortisone sodium succinate, up to 100 mg
- J1726 Injection, hydroxyprogesterone caproate, (Makena), 10 mg
- J1729 Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
- J1730 Diazoxide, up to 300 mg
- J1738 Meloxicam, 1mg
- J1740 Ibandronate sodium, 1 mg
- J1741 Injection, ibuprofen, 100 mg
- J1745 Infliximab, 10 mg
- J1746 Ibalizumab-uiyk, 10 mg
- J1750 Iron dextran, 50 mg
- J1756 Iron sucrose, 1 mg
- J1786 Imiglucerase, 10 units
- J1790 Droperidol, up to 5 mg
- J1800 Propranolol HCl, up to 1 mg
- J1815 Insulin, per 5 units

J1817 Insulin (i.e., insulin pump) per 50 units (Administered under direct physician supervision, not for self-administration) J1823 Inebilizumab-cdon, 1 mg J1826 Interferon beta-1a, 30 mcg J1830 Interferon beta-1b, 0.25 mg (Administered under direct physician supervision, not for self-administration) J1840 Kanamycin sulfate, up to 500 mg J1850 Kanamycin sulfate, up to 75 mg J1885 Ketorolac tromethamine, per 15 mg J1890 Cephalothin sodium, up to 1 gm J1930 Lanreotide, 1 mg J1931 Laronidase, 0.1 mg J1940 Furosemide, up to 20 mg J1943 Aripiprazole lauroxil (aristada initio), 1 mg Aripiprazole lauroxil (aristada), 1 mg J1944 Leuprolide acetate (for depot suspension), per 3.75 mg J1950 Leuprolide acetate for depot suspension (fensolvi), per .25 mg J1951 Levocarnitine, per 1 gm J1955 Levorphanol tartrate, up to 2 mg J1960 Hyoscyamine sulfate, up to 0.25 mg J1980 Chlordiazepoxide HCl, up to 100 mg J1990 Lidocaine HCI for intravenous infusion, 10 mg J2001 Lincomycin HCI, up to 300 mg J2010 Lorazepam, 2 mg J2060 J2150 Mannitol, 25% in 50 ml Meperidine HCl, per 100 mg J2175 Methylergonovine maleate, up to 0.2 mg J2210 Micafungin sodium, 1 mg J2248 J2260 Milrinone lactate, per 5 mg J2270 Morphine sulfate, up to 10 mg Morphine sulfate, preservative-free for epidural or J2274 intrathecal use, 10 mg Ziconotide, 1 mcg J2278 Naloxone hydrochloride, per 1 mg J2310 Nandrolone decanoate, up to 50 mg J2320 J2323 Natalizumab, 1 mg J2350 Ocrelizumab, 1 mg J2353 Octreotide, depot form for intramuscular injection, 1 mg J2355 Oprelvekin, 5 mg J2357 Omalizumab, 5 mg J2358 Olanzapine, long-acting, 1 mg J2360 Orphenadrine citrate, up to 60 mg Phenylephrine HCI, up to 1 ml J2370 J2405 Ondansetron HCI, per 1 mg Oritavancin (kimyrsa), 10 mg J2406 Version 2022-2

J2407	Oritavancin, 10 mg
J2410	Oxymorphone HCl, up to 1 mg
J2425	Palifermin, 50 mg
	Paliperidone palmitate extended release, 1 mg
J2430	Pamidronate disodium, per 30 mg
	Papaverine HCl, up to 60 mg
J2460	Oxytetracycline HCl, up to 50 mg Palonosetron HCl, 25 mcg
	Pasireotide long acting, 1 mg
	Pegademase bovine, 25 IU
J2506	Pegfilgrastim, excludes biosimilar, 0.5 mg
	Penicillin G procaine, aqueous, up to 600,000 units
J2513	Pentastarch, 10% solution, 100 ml
J2515	Pentobarbital sodium, per 50 mg
J2540	Penicillin G potassium, up to 600,000 units
J2545	Pentamidine isethionate, inhalation solution, FDA-approved final product, non- compounded,
	administered through DME, unit dose form, per 300 mg
J2550	Promethazine HCI, up to 50 mg
J2560	Phenobarbital sodium, up to 120 mg
J2590	Oxytocin, up to 10 units
J2597	Desmopressin acetate, per 1 mcg
J2650	Prednisolone acetate, up to 1 ml
J2670	Tolazoline HCl, up to 25 mg
J2675	Progesterone, per 50 mg
J2680	Fluphenazine decanoate, up to 25 mg
J2690	Procainamide HCI, up to 1 gm
J2700	Oxacillin sodium, up to 250 mg
J2710	Neostigmine methylsulfate, up to 0.5 mg
J2720	Protamine sulfate, per 10 mg
J2730	Pralidoxime chloride, up to 1 gm
<u>J2760</u>	Phentolamine mesylate, up to 5 mg
J2765	Metoclopramide HCl, up to 10 mg
J2780	Ranitidine HCI, 25 mg
J2783	Rasburicase, 0.5 mg
J2794	Risperidone, (Risperdal consta), 0.5 mg
J2796	Romiplostim, 10 micrograms
J2797	Rolapitant, 0.5 mg
J2798	Risperidone (perseris), 0.5 mg
J2800	Methocarbamol, up to 10 ml
J2820	Sargramostim (GM-CSF), 50 mcg
J2860	Siltuximab, 10 mg
J2910	Aurothioglucose, up to 50 mg
J2916	Sodium ferric gluconate complex in sucrose injection, 12.5 mg
J2920	Methylprednisolone sodium succinate, up to 40 mg¬
J2930	Methylprednisolone sodium succinate, up to 125 mg
Version	2022-2

J2940	Somatrem, 1 mg
J2941	Somatropin, 1 mg
J2995	Streptokinase, per 250,000 IU
J3000	Streptomycin, up to 1 gm
J3030	Sumatriptan succinate, 6 mg
J3031	F <mark>re</mark> manezumab-vfrm, 1 mg
	(Administered under direct physician supervision, not for self-administration)
J30 <mark>32</mark>	Eptinezumab-jjmr, 1 mg
J3060	Taliglucerace alfa, 10 units
J307 <mark>0</mark>	Pentazocine, 30 mg
J30 <mark>90</mark>	Tedizolid phosphate, 1 mg
J3095	Televancin, 10 mg
J3105	Terbutaline sulfate, up to 1 mg
J3111	Romosozumab-aqqg, 1 mg
J3121	Testoster <mark>one</mark> , enanthate, 1 mg
J3145	Testoster <mark>on</mark> e, un <mark>dec</mark> anoate, 1 mg
J3230	Chlorpromazine HCl, up to 50 mg
J3240	Thyrotropin alph <mark>a,</mark> 0.9 mg. provided in 1.1 mg
J3241	Teprotumumab-trbw, 10 mg
J3245	Tildrakizumab, 1 mg
J3250	Trimethobenzamide HCI, up to 200 mg
J3260	Tobramycin sulfate, up to 80 mg
J3262	Tocilizumab, 1 mg
J3265	Torsemide, 10 mg/ml
J3280	Thiethylperazine maleate, up to 10 mg
J3285	Treprostinil, 1 mg
J3300	Triamcinolone acetonide, preservative free, 1 mg
J3301	Triamcinolone acetonide, not otherwise specified, 10 mg
J3302	Triamcinolone diacetate, per 5 mg
J3303	Triamcinolone hexacetonide, per 5 mg
J3305	Trimetrexate glucuronate, per 25 mg
J3310	Perphenazine, up to 5 mg
J3315	Triptorelin pamoate, 3.75 mg
J3316	Triptorelin, extended-release, 3.75 mg
J3320	Spectinomycin dihydrochloride, up to 2 gm
J3357	Ustekinumab, for subcutaneous injection, 1 mg
J3358	Ustekinumab, for intravenous injection, 1 mg
J3360	Diazepam, up to 5 mg
J3364	Urokinase, 5000 IU vial
J3370	Vancomycin HCI, 500 mg
J3380	Vedolizumab, 1 mg
J3397	-
J3400	Triflupromazine HCl, up to 20 mg
J3410	Hydroxyzine HCl, up to 25 mg
J3411	Thiamine HCl, 100 mg
Version	

- J3415 Pyridoxine HCl, 100 mg
- J3420 Vitamin B-12 cyanocobalamin, up to 1000 mcg
- J3430 Phytonadione, (vitamin K), per 1 mg
- J3470 Hyaluronidase, up to 150 units
- J3475 Magnesium sulfate, per 500 mg
- J3480 Potassium chloride, per 2 meq
- J3489 Zoledronic acid, 1 mg
- J3490 Unclassified drugs
- J3520 Edetate disodium, per 150 mg
- J3590 Unclassified Biologics
- J3591 Unclassified drug or biological used for ESRD on dialysis

MISCELLANEOUS DRUGS AND SOLUTIONS

Codes followed by an ^ do not require an NDC to be provided when billed.

- A4216[^] Sterile water, saline and/or dextrose diluent/flush, 10 ml
- A4218[^] Sterile saline or water, metered dose dispenser, 10 ml
- J7030 Infusion, normal saline solution (or water), 1000 cc
- J7040 Infusion, normal saline solution (or water), sterile (500 ml = 1 unit)
- J7042 5% dextrose/normal saline (500 ml = 1 unit)
- J7050 Infusion, normal saline solution (or water), 250 cc
- J7060 5% dextrose/water (500 ml = 1 unit)
- J7070 Infusion, D5W, 1000 cc
- J7100 Infusion, Dextran 40, 500 ml
- J7110 Infusion, dextran 75, 500 ml
- J7120 Ringers lactate infusion, up to 1000 cc
- J7121 5% Dextrose in lactated ringers infusion, up to 1000 cc
- J7131 Hypertonic saline solution, 1 ml
- J7294 Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hour
- J7295 Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each
- J7296 Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg
- J7297 Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 3 year duration
- J7298 Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 5 year duration
- J7300 Intrauterine copper contraceptive
- J7301 Levonorgestrel-releasing intrauterine contraceptive system, 13.5 mg
- J7304 Contraceptive supply, hormone containing patch, each
- J7306 Levonorgestrel (contraceptive) implant system, including implants and supplies
- J7307 Etonogestrel (contraceptive) implant system, including implant and supplies
- J7308 Aminolevulinic acid HCl for topical administration, 20%, single unit dosage form (354 mg)
- J7321[^] Hyaluronan or derivative, Hyalgan or Supartz, or visco-3, for intra-articular injection, per dose
- J7323[^] Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
- J7324[^] Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
- J7325[^] Hyaluronan or derivative, Synvisc or Synvisc-One, intra-articular
- J7326 Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
- J7336 Capsaicin 8% patch, per square centimeter
- Version 2022-2

- J7345 Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg
- J7501 Azathioprine, parenteral (eg Imuran), 100 mg
- J7504 Lymphocyte immune globulin, antithymocyte globulin equine, parenteral, 250 mg
- J7606 Formoterol fumarate, inhalation solution, non-compounded, administered through DME, unit dose form, 20 mcg
- J7611 Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1mg
- J7612 Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg
- J7613 Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg
- J7614 Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME. Unit dose. 0.5 mg
- J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, non-compounded, administered through DME
- J7627 Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg
- J7628 Bitolterol mesylate, inhalation solution, compounded product, administered through DME, concentrated form, per mg
- J7631 Cromolyn sodium, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 mg
- J7640 Formoterol, inhalation solution, compounded product, administered through DME, unit dose form, 12 mcg
- J7644 Ipratropium bromide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg
- J7648 Isoetharine HCI, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
- J7649 Isoetharine HCI, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg
- J7658 Isoproterenol HCI, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
- J7668 Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per 10 mg
- J7669 Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 mg
- J7674 Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg
- J7682 Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, 300 mg
- J7999 Compounded drug, not otherwise classified
- J8501 Aprepitant, oral, 5 mg
- J8540 Dexamethasone, oral, 0.25 mg
- J8650 Nabilone, oral, 1 mg
- J9037 Belantamab mafodontin-BLMF, 0.5 mg
- J9226 Histrelin implant (Supprelin LA), 50 mg

- J9349 Tafasitamab-CXIX, 2 mg
- J9359 Loncastuximab tesirine-lpyl, 0.075 mg
- Q0138 Ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use)
- Q5101 Filgrastim -sndz, biosimilar, (zarxio), 1 microgram
- Q5103 Inflectra (Infliximab-dyyb), biosimilar, 10 mg
- Q5104 Renflexis (Infliximab-abda), biosimilar, 10 mg
- Q5108 Pegfilgrastim-jmdb, biosimilar, 0.5 mg
- Q5111 Pegfilgrastim-cbqv, biosimilar, 0.5 mg
- Q5112 Trastuzumab-dttb, biosimilar, 10 mg
- Q5119 Rituximab-pvvr, biosimilar, 10 mg
- Q5120 Pegfilgrastim-bmez, biosimilar, 0.5 mg
- Q5121 Infliximab-axxq, biosimilar, 10 mg
- Q5123 Rituximab-arrx, biosimilar, (riabni), 10 mg
- Q9991 Buprenorphone extended-release, less than or equal to 100 mg
- Q9992 Buprenorphone extended-release, greater than or 100 mg

HYDRATION, THERAPEUTIC, PROPHYLACTIC, DIAGNOSTIC INJECTIONS and INFUSIONS, and CHEMOTHERAPY and OTHER HIGHLY COMPLEX DRUG or HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

Physician work related to hydration, injection, and infusion services predominantly involves affirmation of treatment plan and direct supervision of staff.

If a significant separately identifiable Evaluation and Management service is performed, the appropriate E/M service code should be reported using modifier '25' in addition to 96360-96549. For same day E/M service a different diagnosis is not required.

If performed to facilitate the infusion or injection, the following services are included and are not reported separately:

- a. Use of local anesthesia
- b. IV start
- c. Access to indwelling IV, subcutaneous catheter or port
- d. Flush at conclusion of infusion
- e. Standard tubing, syringes, and supplies

When multiple drugs are administered, report the service(s) and the specific materials or drugs for each.

When administering multiple infusions, injections or combinations, only one "initial" service code should be reported, unless protocol requires that two separate IV sites must be used. If an injection or infusion is of a subsequent or concurrent nature, even if it is the first such service within that group of services, then a subsequent or concurrent code from the appropriate section should be reported (eg, the first IV push given subsequent to an initial one-hour infusion is reported using a subsequent IV push code). When these codes are reported by the physician, the "initial" code that best describes the key or primary reason for the encounter should always be reported irrespective of the order in **Version 2022-2**

which the infusions or injections occur. When reporting codes for which infusion time is a factor, use the actual time over which the infusion is administered. Intravenous or intra-arterial push is defined as: (a) an injection in which the health care professional who administers the substance/drug is continuously present to administer the injection and observe the patient, or (b) an infusion of 15 minutes or less.

HYDRATION

Codes 96360-96361 are intended to report a hydration IV infusion to consist of a pre-packaged fluid and electrolytes (eg, normal saline, D5-1/2 normal saline+30mEq KCl/liter), but are not used to report infusion of drugs or other substances. Hydration IV infusions typically require direct physician supervision for purposes of consent, safety oversight, or intraservice supervision of staff. Typically such infusions require little special handling to prepare or dispose of, and staff that administer these do not typically require advanced practice training. After initial set-up, infusion typically entails little patient risk and thus little monitoring. These codes are not intended to be reported by the physician in the facility setting.

96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour
 (Do not report 96360 if performed as a concurrent infusion service)
 (Do not report intravenous infusion for hydration of 30 minutes or less)

96361 each additional hour

(List separately in addition to primary procedure) (Use 96361 in conjunction with 96360)

(Report 96361 for hydration infusion intervals of greater than 30 minutes beyond 1 hour increments)

(Report 96361 to identify hydration if provided as a secondary or subsequent service after a different initial service [96360, 96365, 96409, 96413] is administered through the same IV access)

THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC INJECTIONS AND INFUSIONS (EXCLUDES CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION)

A therapeutic, prophylactic or diagnosis IV infusion or injection (other than hydration) is for the administration of substances/drugs. When fluids are used to administer the drug(s), the administration of the fluid is considered incidental hydration and is not separately reportable. These services typically require direct physician supervision for any or all purposes of patient assessment, provision of consent, safety oversight, and intra-service supervision of staff. Typically, such infusions require special consideration to prepare, dose or dispose of, require practice training and competency for staff who administer the infusions, and require periodic patient assessment with vital sign monitoring during the infusion. These codes are not intended to be reported by the physician in the facility setting.

(Do not report 96365-96371 with codes for which IV push or infusion is an inherent part of the procedure [eg, administration of contrast material for a diagnostic imaging study])

96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drugs); up		
	to 1 hour		
96366	each additional hour		
	(List separately in addition to primary procedure)		
	(Report 96366 in conjunction with 96365, 96367)		
	(Report 96366 for additional hour[s] of sequential infusion)		
	(Report 96366 for infusion intervals of greater than 30 minutes beyond 1 hour increments)		
96367	additional sequential infusion of a new drug/substance, up to 1 hour		
	(List separately in addition to primary procedure)		
	(Report 96367 in conjunction with 96365, 96409, 96413 to identify the infusion of a new		
	drug/substance provided as a secondary or subsequent service after a different initial		
	service is administered through the same IV access.		
	(Report 96367 only once per sequential infusion of same infusate mix)		
96368	concurrent infusion		
	(List separately in addition to primary procedure)		
	(Report 96 <mark>368</mark> only once per encounter)		
	(Report 96 <mark>368</mark> in conjunction with 96365, 96366, 96413, 96415, 96416)		
96369	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1		
	hour, including pump set-up and establishment of subcutaneous infusion site(s)		
96370	each additional hour		
	(List separately in addition to primary procedure)		
	Use 96370 in conjunction with 96369)		
	(Use 96370 for infusion intervals of greater than 30 minutes beyond 1 hour increments)		
96371	additional pump set-up with establishment of new subcutaneous infusion site(s)		
	(List separately in addition to primary procedure)		
	Use 96371 in conjunction with 96369)		
	(Use 96369, 96371 only once per encounter)		
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous		

CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

Procedures 96405-96549 are independent of the patient's office visit. Either may occur independently from the other on any given day, or they may occur sequentially on the same day. Intravenous chemotherapy injections are administered by a physician, a nurse practitioner or by a qualified assistant under supervision of the physician or nurse practitioner. Preparation of chemotherapy agent(s) is included in the service for administration of the agent.

INJECTION AND INTRAVENOUS INFUSION CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

96405 Chemotherapy administration; intralesional; up to and including 7 lesions

or intramuscular (Bill on one claim line for multiple injections)

96406 intralesional, more than 7 lesions

96409 intravenous, push technique, single or initial substance/drug

96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

(Report 96361 to identify hydration if administered as a secondary or subsequent service in association with 96413 through the same IV assess)

(Report 96366, 96367, to identify therapeutic, prophylactic, or diagnostic drug infusion or injection, if administered as a secondary or subsequent service in association with 96413 through the same IV access)

96415 each additional hour
 (List separately in addition to primary procedure)
 (Use 96415 in conjunction with 96413)
 (Report 96415 for infusion intervals of greater than 30 minutes beyond 1-hour

increments)

96416 initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump

INTRA-ARTERIAL CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

- 96420 Chemotherapy administration, intra-arterial; push technique
- 96422 infusion technique, up to 1 hour
- 96423 infusion technique, each additional hour
 (List separately in addition to primary procedure)
 (Use 96423 in conjunction with code 96422)
 (Report 96423 for infusion intervals of greater than 30 minutes beyond 1-hour increments)
- 96425 infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump

OTHER INJECTION AND INFUSION SERVICES

- 96440 Chemotherapy administration into pleural cavity, requiring and including thoracentesis
- 96446 Chemotherapy administration into the peritoneal cavity via indwelling port or catheter
- 96450 Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture
- 96521 Refilling and maintenance of portable pump
- 96522 Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic, (eg, intravenous, intra-arterial)
- 96542 Chemotherapy injection, subarachnoid or intraventricular via subcutaneous reservoir, single or multiple agents
- 96549 Unlisted chemotherapy procedure
- J9999 Not otherwise classified, antineoplastic drugs

CHEMOTHERAPY DRUGS

(Maximum fee is for chemotherapy drug only and does not include the administration procedures as listed above)

NOTE: The maximum fees for these drugs are adjusted periodically by the State to reflect the estimated acquisition cost. Insert actual acquisition cost per dose in amount charged field on claim form. For codes listed BR/Report required, also attach itemized invoice to claim form.

Reimbursement for drugs furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

Codes followed by an ^ do not require an NDC to be provided when billed.

Doxorubicin HCL (Adriamycin), 10 mg J9000 J9015 Aldesleukin, per single use vial Arsenic trioxide, 1 mg (Trisenox) J9017 J9020 Asparaginase (Elspar) 10,000 units Asparaginase, recombinant, (rylaze), 0.1 mg J9021 J9022 Atezolizumab, 10 mg J9023 Avelumab, 10 mg J9025 Azacitidine, 1 mg J9027 Clofarabine, 1 mg J9030 BCG (intravesical) per 1mg J9032 Belinostat, 10 mg Bendamustine HCL (Treanda), 1 mg J9033 Bendamustine HCL (Bendeka), 1 mg J9034 J9035 Bevacizumab, 10 mg J9036 Bendamustine hydrochloride, 1 mg J9037 Belantamab mafodontin-blmf, 0.5 mg Blinatumomab, 1 microgram J9039 Bleomycin sulfate (Blenoxane), 15 units J9040 Bortezomib (velcade), 0.1 mg J9041 Carboplatin, 50 mg J9043 Bortezomib, not otherwise specified, 0.1 mg J9044 J9045 Carboplatin, 50 mg J9050 Carmustine, 100 mg J9055 Cetuximab, 10 mg J9057 Copanlisib, 1 mg Cisplatin, powder or solution, 10 mg J9060 J9061 Amivantamab-vmjw, 2 mg J9065 Cladribine, per 1 mg Cyclophosphamide, 100 mg J9070 Cyclophosphamide, (auromedics), 5 mg J9071 Cytarabine liposome, 10 mg J9098

J9100	Cytarabine (Cytosar-U), 100 mg	
J9118	Calaspargase pegol-mknl, 10 units	
J9119	Cemiplimab-rwlc, 1 mg	
J9120	Dactinomycin (Cosmegen), 0.5 mg	
J9130	Dacarbazine, 100 mg	
J9144	Daratumumab, 10 mg and hyaluronidase-fihj	
J9145	Daratumumab, 10 mg	
J9150	Daunorubicin HCL, 10 mg	
J9151	Daunorubicin citrate, liposomal formulation, 10 mg	
J915 <mark>3</mark>	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	9
J91 <mark>55</mark>	Degarelix, 1 mg	
J9160	Denileukin diftitox, 300 mcg	
J9165	Diethylstilb <mark>es</mark> trol diphosphate, 250 mg	
J9171	Docetaxel, 1 mg	
J9173	Injection, <mark>du</mark> rvalumab, 10 mg	
J9176	Elotuzum <mark>ab</mark> , 1 mg	
J9177	Enfortumab ved <mark>otin</mark> -ejfv 0.25mg	
J9178	Epirubicin HCL, 2 mg	
J9179	Eribulin mesylate, 0.1mg	
J9181	Etoposide, 10 mg	
J9185	Fludarabine phosphate, 50 mg	
J9190	Fluorouracil, 500 mg	
J9198	Gemcitabine hydrochloride, (infugem), 100 mg	
J9200	Floxuridine (FUDR), 500 mg	
J9201	Gemcitabine HCI, not otherwise specified, 200 mg	
J9202	Goserelin acetate implant per 3.6 mg	
J9203	Gemtuzumab ozogamicin, 0.1 mg	
J9204	Mogamulizumab-kpkc, 1 mg	
J9205	Irinotecan liposome, 1 mg	
J9206	Irinotecan, 20 mg	
J9207	Ixabepilone, 1 mg	
J9208	Ifosfamide, 1 gm	
J9209	Mesna, 200 mg	
J9210	Emapalumab-lzsg, 1 mg	
J9211	Idarubicin HCI, 5 mg	
J9212	Interferon Alfacon-1, Recombinant, 1 mcg	
J9213	Interferon, Alfa-2A, Recombinant, 3 million units	
J9214	Interferon, Alfa-2B, Recombinant, 1 million units	
J9215	Interferon, Alfa-N3, (Human Leukocyte Derived), 250,000 IU	
J9216	Interferon, Gamma 1-B, 3 million units	
J9217	Leuprolide acetate (for Depot Suspension), 7.5 mg	
J9218	Leuprolide acetate, per 1 mg	
J9219^	Leuprolide acetate implant, 65 mg	
J9223	Lurbinectedin, 0.1 mg	
J9225	Histrelin implant (Vantas), 50 mg	
Version	2022-2	Dama 52 of 64

J9226 Histrelin implant (Supprelin LA), 50 mg Isatuximab-irfc, 10 mg J9227 J9228 Ipilimumab, 1mg J9229 Injection, inotuzumab ozogamicin, 0.1 mg Mechlorethamine HCI (nitrogen mustard), 10 mg J9230 J9245 Melphalan HCl, 50 mg Melphalan (evomela), 1 mg **J9246** J9250 Methotrexate sodium, 5 mg Methotrexate sodium, 50 mg J9260 J9261 Nelarabine, 50 mg Oxaliplatin (Eloxatin), 0.5 mg J9263 J9264 Paclitaxel protein-bound particles, 1 mg J9266 Pegaspargase, per single dose vial J9267 Paclitaxel, 1 mg J9268 Pentostatin, per 10 mg Tagrxofusp-erzs, 10 micrograms J9269 Plicamycin, 2.5 mg J9270 J9271 Pembrolizumab, 1 mg Dostarlimab-gxly, 10 mg J9272 Tisotumab vedotin-tftv, 1 mg J9273 J9280 Mitomycin, 5 mg Mitomycin pyelocalyceal instillation, 1 mg J9281 Olaratumab, 10 mg J9285 J9293 Mitoxantrone HCI, per 5 mg Necitumumab, 1 mg J9295 J9299 Nivolumab, 1 mg J9301 Obinutuzumab, 10 mg J9302 Ofatumumab, 10 mg J9303 Panitumumab, 10 mg J9304 Pemetrexed (pemfexy), 10 mg J9305 Pemetrexed, 10 mg Pralatrexate, 1 mg J9307 J9308 Ramucirumab, 5 mg Polatuzumab vedotin-piig, 1 mg J9309 Injection, rituximab 10 mg and hyaluronidase J9311 J9312 Rituximab, 10 mg Moxetumomob pasudotox-tdfk, 0.01 mg J9313 Pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg J9316 Sacituzumab govitecan-hziy, 2.5 mg J9317 J9318 Romidepsin, non-lyophilized, 0.1 mg Romidepsin, lyophilized, 0.1 mg J9319 J9320 Streptozocin, 1 gm Talimogene laherparepvec, per 1 million plaque forming units J9325 J9330 Temsirolimus, 1 mg J9340 Thiotepa, 15 mg J9348 Naxitamab-gqgk, 1 mg Tafasitamab-CXIX, 2 mg J9349 J9351 Topotecan, 0.1 mg Version 2022-2

- J9352 Trabectedin, 0.1 mg
- J9353 Margetuximab-cmkb, 5 mg
- J9354 Ado-trastuzumab emtansine, 1 mg
- J9355 Trastuzumab, 10 mg
- J9356 Trastuzumab, 10 mg/Hyaluronidase-oysk
- J9357 Valrubicin, intravesical, 200 mg
- J9358 Fam-trastuzumab deruxtecan-nxki,1mg
- J9360 Vinblastine sulfate, 1 mg
- J9370 Vincristine sulfate, 1 mg
- J9390 Vinorelbine Tartrate, 10 mg
- J9395 Fulvestrant (Faslodex), 25 mg
- J9600 Porfimer sodium, 75 mg
- J9999 Not Otherwise Classified, Antineoplastic Drugs
- Q0174 Thiethylperazine Maleate, 10 mg, oral
- Q0177 Hydroxyzine Pamoate, 25 mg, oral
- Q2017 Teniposide, 50 mg
- Q2050 Doxorubicin HCL liposomal, NOS, 10 mg
- Q5107 Bevacizumab-awwb, biosimilar, 10 mg
- Q5113 Trastuzumab pkrb, biosimilar, 10 mg
- Q5114 Trastuzumab-dkst, biosimilar, 10 mg
- Q5115 Rituximab-abbs, biosimilar, 10 mg
- Q5116 Trastuzumab-qyyp, biosimilar, 10 mg
- Q5117 Trastuzumab-anns, biosimilar, 10 mg
- Q5118 Bevacizumab-bvzr, biosimilar, 10 mg

<u>PSYCHIATRY</u>

Note: To bill for the following codes, you must be certified by the NYS Education Department as a Nurse Practitioner in Psychiatry (Profession Code 040)

- 90785 Interactive complexity (List separately in addition to primary procedure)
- 90791 Psychiatric diagnostic evaluation
- 90792 Psychiatric diagnostic evaluation with medical services

PSYCHOTHERAPY

- 90832 Psychotherapy, 30 minutes with patient
- 90833 Psychotherapy, 30 minutes with patient when performed with an evaluation and management service

(List separately in addition to the code for primary procedure)

- 90834 Psychotherapy, 45 minutes with patient
- 90836 Psychotherapy, 45 minutes with patient when performed with an evaluation and management service

(List separately in addition to the code for primary procedure)

90837 Psychotherapy, 60 minutes, with patient

90838 Psychotherapy, 60 minutes with patient when performed with an evaluation and management service

(List separately in addition to the code for primary procedure)

OTHER PSYCHOTHERAPY

- 90846 Family psychotherapy (without the patient present), 50 minutes
- 90847 Family psychotherapy (conjoint psychotherapy) (with patient present), 50 minutes
- 90849 Multiple-family group psychotherapy
- 90853 Group psychotherapy (other than of a multiple-family group)

OTHER PSYCHIATRIC SERVICES OR PROCEDURES

90863 Pharmacologic management, including prescription and review of medication, when performed with psychotherapy services (List separately in addition to primary procedure)

SPECIAL OPHTHALMOLOGICAL SERVICES

- 92071 Fitting of contact lens for treatment of ocular surface disease (Do not report 92071 in conjunction with 92072)
- 92072 Fitting of contact lens for management of keratoconus, initial fitting (Do not report 92072 in conjunction with 92071)

SPECIAL OTORHINOLARYNGOLOGIC SERVICES

Diagnostic or treatment procedures that are reported as evaluation and management services (eg, otoscopy, anterior rhinoscopy, tuning fork test, removal of non-impacted cerumen) are not reported separately.

Special otorhinolaryngologic services are those diagnostic and treatment services not included in an Evaluation and Management service. These services are reported separately, using codes 92502-92700.

VESTIBULAR FUNCTION TESTS, WITH RECORDING (eg, ENG)

- 92537 Caloric vestibular test with recording, bilateral; bithermal (ie, one warm and one cool irrigation in each ear for a total of four irrigations)
- 92538 monothermal (ie, one irrigation in each ear for a total of two irrigations)
- 92540 Basic vestibular evaluation, includes spontaneous nystagmus test with eccentric gaze fixation nystagmus, with recording, positional nystagmus test, minimum of 4 positions, with recording, optokinetic nystagmus test, bidirectional foveal and peripheral stimulation, with recording, and oscillating tracking test, with recording

- 92541 Spontaneous nystagmus test, including gaze and fixation nystagmus, with recording
- 92542 Positional nystagmus test, minimum of 4 positions, with recording
- 92544 Optokinetic nystagmus test, bidirectional, foveal or peripheral stimulation, with recording
- 92545 Oscillating tracking test, with recording
- 92546 Sinusoidal vertical axis rotational testing
- 92517 Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP)
- 92518 Ocular (oVEMP)

92519 Cervical (cVEMP) and ocular (oVEMP)

AUDIOLOGIC FUNCTION TESTS

The audiometric tests listed below require the use of calibrated electronic equipment, recording of results and a report with interpretation. Hearing tests (such as whispered voice, tuning fork) that are otorhinolaryngologic Evaluation and Management services are not reported separately. All services include testing of both ears.

- 92550 Tympanometry and reflex threshold measurements
- 92551 Screening test, pure tone, air only
- 92552 Pure tone audiometry (threshold); air only
- 92553 air and bone
- 92555 Speech audiometry threshold
- 92556 with speech recognition
- 92557 Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)
- 92563 Tone decay test
- 92565 Stenger test, pure tone
- 92567 Tympanometry (impedance testing)
- 92568 Acoustic reflex testing; threshold
- 92570 Acoustic immittance testing, includes tympanometry (impedance testing), acoustic reflex threshold testing, and acoustic reflex decay testing
- 92571 Filtered speech test
- 92587 Distortion product evoked otoacoustic emissions; limited evaluation (to confirm the presence or absence of hearing disorder, 3-6 frequencies) or transient evoked otoacoustic emissions, with interpretation and report
- 92650 Auditory evoked potentials; screening of auditory potential with broadband stimuli, automated analysis
- 92651 for hearing status determination, broadband stimuli, with interpretation and report
- 92652 for threshold estimation at multiple frequencies, with interpretation and report
- 92653 neurodiagnostic, with interpretation and report

CARDIOVASCULAR

CARDIOGRAPHY

93000 Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report 93010 interpretation and report only

PULMONARY

Codes 94010-94799 include laboratory procedure(s) and interpretation of test results.

- 94010 Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
- 94011 Measurement of spirometric forced expiratory flows in an infant or child through 2 years of age
- 94012 Measurement of spirometric forced expiratory flows, before and after bronchodilator, in an infant or child through 2 years of age
- 94013 Measurement of lung volumes (ie, functional residual capacity [FRC], forced vital capacity [FVC], and expiratory reserve volume [ERV] in an infant or child through 2 years of age
- 94014 Patient-initiated spirometric recording per 30-day period of time; includes reinforced education, transmission of spirometric tracing, data capture, analysis of transmitted data, periodic recalibration and physician review and interpretation
- 94016 physician review and interpretation only
- 94060 Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
- 94200 Maximum breathing capacity, maximal voluntary ventilation
- 94625 Physician or other qualified health care professional services for outpatient pulmonary rehabilitation; without continuous oximetry monitoring (per session)
- 94626 with continuous oximetry monitoring (per session)
- 94644 Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour
- 94645 each additional hour (List separately in addition to primary procedure)
- 94664 Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device (94664 can be reported one time only per day of service)

ALLERGY AND CLINICAL IMMUNOLOGY

Immunotherapy (desensitization, hyposensitization) is the parenteral administration of allergenic extracts as antigens at periodic intervals, usually on an increasing dosage scale to a dosage which is maintained as maintenance therapy. Indications for immunotherapy are determined by appropriate diagnostic procedures coordinated with clinical judgment and knowledge of the natural history of allergic diseases.

SENSITIVITY TESTING (Maximum fees include reading of test)

86580 Skin test; tuberculosis, intradermal

ALLERGEN IMMUNOTHERAPY

- 95115 Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
- 95117 2 or more injections

ENDOCRINOLOGY

- 95250 Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified healthcare professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording
- 95251 analysis, interpretation and report

MISCELLANEOUS SERVICES

- 93797 Physician services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session)
- 93798 with continuous ECG monitoring (per session)
- 95990 Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular), includes electronic analysis of pump, when performed
- 96040 Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family
- 96110 Developmental screening (eg, developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument
- 97542# Wheelchair management (eg, assessment, fitting, training), each 15 minutes (up to a maximum of 2 hours)
- 98960 Education and training for patient self-management by a qualified, non physician health care professional using a standardized curriculum, face-to-face with the patient (could include caregiver/family) each 30 minutes; individual patient
- 98961 2-4 patients
- 98962 5-8 patients
- 99050 Services provided in the office at times other than regularly scheduled office hours, or days when the office is normally closed (eg, holidays, Saturday or Sunday), in addition to basic service
- 99051 Service(s) provided in the office during regularly scheduled evening, weekend, or holiday office hours, in addition to basic service
- 99070 Supplies and materials (except spectacles), provided by the physician over and above those usually included with the office visit or other services rendered (List drugs, trays, supplies, or materials provided)
- 99091 Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to to the physician or other qualified healthcare professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time, each 30 days
- 99170 Anogenital examination, magnified in childhood for suspected trauma, including image recording when performed
- 99188 Application of topical fluoride varnish by a physician or other qualified health care professional
- G0108 Diabetes outpatient self-management training services, individual, per 30 minutes
- G0109 group session (2 or more), per 30 minutes
- G0372 Physician service required to establish and document the need for a power mobility device

- G8431 Screening for clinical depression is documented as being positive and a follow-up plan is documented
- G8510 Screening for clinical depression is documented as being negative, a follow-up plan is not required
- H0049 Alcohol and/or drug screening
- H0050 Alcohol and/or drug services, brief intervention, per 15 minutes
- Q3014 Telehealth originating site facility fee
- Q5106 Injection, epoetin alfa-epbx, biosimilar; (retacrit) (for non-ESRD use), 1000 units
- S0013 Esketamine, nasal spray, 1 mg
- S9445 Patient education, not otherwise classified, non-physician provider, individual, per session. (The initial lactation counseling session should be a minimum of 45 minutes. Follow up session(s) should be a minimum of 30 minutes.)
- S9446 Patient education, not otherwise classified, non-physician provider, individual, per session. (The initial lactation counseling session should be a minimum of 45 minutes. Follow up session(s) should be a minimum of 30 minutes.) NYS Medicaid will provide reimbursement for separate and distinct breastfeeding services provided by International Board Certified Lactation Consultants (IBCLCs) credentialed by the IBCLCE. For additional information see:

http://www.health.ny.gov/health_care/medicaid/program/update/2013/2013-03.htm#fee

T1013 Sign language or oral interpretive services, per 15 minutes

SURGERY SECTION

GENERAL INFORMATION AND RULES

- 1. **FEES**: Fees for office, home and hospital visits and other medical services are listed in the section entitled MEDICINE.
- FOLLOW UP (F/U) DAYS: Listed dollar values for all surgical procedures include the surgery and the follow-up care for the period indicated in days in the column headed "F/U Days". Necessary follow-up care beyond this listed period is to be added on a fee-for-service basis. (See modifier -24)
- 3. **BY REPORT**: When the value of a procedure is indicated as "By Report" (BR), an Operative Report must be submitted with the MMIS claim form for a payment determination to be made. The Operative Report must include the following information:
 - a. Diagnosis (post-operative)
 - b. Size, location and number of lesion(s) or procedure(s) where appropriate
 - c. Major surgical procedure and supplementary procedure(s)
 - d. Whenever possible, list the nearest similar procedure by number according to these studies
 - e. Estimated follow-up period
 - f. Operative time

Failure to submit an Operative Report when billing for a "By Report" procedure will cause your claim to be <u>denied</u> by MMIS.

4. **ADDITIONAL SERVICES**: Complications or other circumstances requiring additional and unusual services concurrent with the procedure(s) or during the listed period of normal follow-up care may warrant additional charges on a fee-for-service basis. (See modifiers -24, -25, -79). When an additional surgical procedure(s) is carried out within the listed period of follow-up care for a previous surgery, the follow-up periods will continue concurrently to their normal terminations.

5. MULTIPLE SURGICAL PROCEDURES:

- a. When multiple or bilateral surgical procedures, which add significant time or complexity to patient care, are performed at the same operative session, the total dollar value shall be the value of the major procedure plus 50% of the value of the lesser procedure(s) unless otherwise specified.
- b. When an incidental procedure (eg, incidental appendectomy, lysis of adhesions, excision of previous scar, puncture of ovarian cyst) is performed through the same incision, the fee will be that of the major procedure only.
- 6. **ASSIST AT SURGERY**: When a physician requests a nurse practitioner or a physician's assistant to participate in the management of a specific surgical procedure in lieu of another physician, by prior agreement, the total value may be apportioned in relation to the responsibility and work done, provided the patient is made aware of the fee distribution according to medical ethics. The value may be increased by 20 percent under these circumstances. The claim for these services will be submitted by the physician using the appropriate modifier.

INTEGUMENTARY SYSTEM

SKIN, SUBCUTANEOUS AND AREOLAR TISSUES

INCISION AND DRAINAGE

- 10060 Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); simple or single
- 10061 complicated or multiple
- 10120 Incision and removal of foreign body, subcutaneous tissues; simple
- 10140 Incision and drainage of hematoma, seroma or fluid collection
- 10160 Puncture aspiration of abscess, hematoma, bulla, or cyst

BIOPSY

- 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion
- 11103 each separate/additional lesion (List separately in addition to code for primary procedure)
- 11104 Punch biopsy of skin (including simple closure, when performed); single lesion
- 11105 each separate/additional lesion (List separately in addition to code for primary procedure)
- 11106 Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion

11107 each separate/additional lesion (List separately in additional to code for primary procedure)

REMOVAL OF SKIN TAGS

Excision (including simple closure) of benign lesions of skin or subcutaneous tissues (eg, neoplasm, cicatricial, fibrous, inflammatory, congenital, cystic lesions), includes local anesthesia. See appropriate size and area below.

11200 Removal of skin tags, multiple fibrocutaneous tags, any area; up to and including 15 lesions

11400 Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.5 cm or less

INTRODUCTION

- 11976 Removal, implantable contraceptive capsules
- 11981 Insertion, drug-delivery implant (ie, bioresorbable, biodegradable, non-biodegradable)
- 11982 Removal, non-biodegradable drug delivery implant
- 11983 Removal with reinsertion, non-biodegradable drug delivery implant

REPAIR

Simple repair is used when the wound is superficial; eg, involving primarily skin and/or subcutaneous tissues without significant involvement of deeper structures, and requires simple one layer closure. FOR CLOSURE WITH ADHESIVE STRIPS, LIST APPROPRIATE EVALUATION AND MANAGEMENT SERVICE ONLY.

Instructions for listing services at time of wound repair.

- 1. The repaired wound(s) should be measured and recorded in centimeters, whether curved, angular or stellate.
- 2. When multiple wounds are repaired, add together the lengths of those in the same classification (see above) and report as a single item.

Simple ligation of vessels in an open wound is considered as part of any wound closure. Simple exploration of nerves, blood vessels or tendons exposed in an open wound is also considered part of the essential treatment of the wound and is not a separate procedure unless appreciable dissection is required.

REPAIR-SIMPLE

- 12001 Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.5 cm or less
- 12002 2.6 cm to 7.5 cm
- 12004 7.6 cm to 12.5 cm
- 12005 12.6 cm to 20.0 cm
- 12011 Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less
- 12013 2.6 cm to 5.0 cm

- 12014 5.1 cm to 7.5 cm
- 12015 7.6 cm to 12.5 cm
- 12016 12.6 cm to 20.0 cm

BURNS, LOCAL TREATMENT

Procedures 16000 and 16020 refer to local treatment of burned surface only.

List percentage of body surface involved and depth of burn.

For necessary related medical services (eg, hospital visits) in management of burned patients, see appropriate services in **Medicine** section.

- 16000 Initial treatment, first degree burn, when no more than local treatment is required
- 16020 Dressings and/or debridement of partial-thickness burns, initial or subsequent; small (less than 5% total body surface area)

DESTRUCTION

- 17000 Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion
- 17003 second through 14 lesions, each (List separately in addition to code for first lesion) (Use 17003 in conjunction with 17000)
- 17004 Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses), 15 or more lesions (Do not report 17004 in conjunction with17000 -17003)
- 17106 Destruction of cutaneous vascular proliferative lesions (eg, laser technique); less than 10 sq cm
- 17107 10.0 to 50.0 sq cm
- 17108 over 50.0 sq cm
- 17110 Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions
- 17111 15 or more lesions
- 17250 Chemical cauterization of granulation tissue (ie,proud flesh)

DIGESTIVE SYSTEM

STOMACH

43762 Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract

FEMALE GENITAL SYSTEM

VULVA AND INTROITUS

DESTRUCTION

56501 Destruction of lesion(s), vulva; simple (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery)

REPAIR

56820 Colposcopy of the vulva;

VAGINA

INTRODUCTION

57150 Irrigation of vagina and/or application of medicament for treatment of bacterial, parasitic, or fungoid disease

ENDOSCOPY

- 57420 Colposcopy of the entire vagina, with cervix if present
- 57452 Colposcopy of the cervix including upper/adjacent vagina;
- 57454 with biopsy(s) of the cervix and endocervical curettage
- 57455 with biopsy(s) of the cervix
- 57456 with endocervical curettage
- 57460 with loop electrode (biopsy(s) of the cervix
- 57461 with loop electrode conization of the cervix
- 57465 Computer-aided mapping of cervix uteri during colposcopy, including optical dynamic spectral imaging and algorithmic quantification of the acetowhitening effect (List separately in addition to code for primary procedure)

CORPUS UTERI

INTRODUCTION

(For materials supplied by a practitioner, see General Information #7)

- 58300 Insertion of intrauterine device (IUD)
- 58301 Removal of intrauterine device (IUD)

MATERNITY CARE

Antepartum care includes usual prenatal services (initial and subsequent history, physical examinations, recording of weight, blood pressure, fetal heart tones, routine chemical urinalysis, maternity counseling).

Postpartum care includes hospital and office visits following vaginal or cesarean section delivery.

For medical complications of pregnancy (toxemia, cardiac problems, neurological problems or other problems requiring additional or unusual services or requiring hospitalization), see services in **MEDICINE** section.

ANTEPARTUM AND POSTPARTUM CARE

Reimbursement amounts for the Medicaid Obstetrical and Maternal Services Program (MOMS) are noted in the **Enhanced Program Fee Schedule**. For information on the MOMS Program see Policy Guidelines.

59412 External cephalic version, with or without tocolysis

- 59425 Antepartum care only; 4-6 visits
- **59426**

7 or more visits

(For 6 or less antepartum encounters, see code 59425)

Note: Antepartum services will no longer require prorated charges. This applies to all prenatal care providers, including those enrolled in the MOMS program. Providers should bill one unit of the appropriate antepartum code after all antepartum care has been rendered using the last antepartum visit as the date of service. Only one antepartum care code will be reimbursed per pregnancy.

59430 Postpartum care only (separate procedure)

(When inpatient postpartum care is provided, see appropriate Hospital Evaluation and Management code(s).)

<u>NERVOUS SYSTÈM</u>

RESERVOIR/PUMP IMPLANTATION

- 62367 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming or refilling
- 62368 with reprogramming
- 62369 with reprogramming and refill

AUDITORY SYSTEM

- 69200 Removal foreign body from external auditory canal; without general anesthesia
- 69210 Removal impacted cerumen requiring instrumentation (report one unit for unilateral **OR** bilateral procedure.)

